CSL / MATCH—02CYTOSOMATIC LABS

RESEARCH MATCHING

Possibility.
Not a promise.

Explore potential research opportunities. Eligibility always rests with the study team.

PRIVATE PRELIMINARY REVIEW

Your research interests

Profile answers and saved studies stay in this browser's memory during your visit. Refreshing clears them. They are not sent to AI, analytics or storage.

This is a preliminary information tool, not a determination of clinical eligibility. Only the study team can confirm eligibility.

No clinical eligibility percentage is calculated. Only age, sex and healthy-volunteer criteria are checked.

My Research Opportunities

NCT05824169Recruiting

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients

Spinal Muscular Atrophy

Why this research matters

Original registry summary

The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 1 (SMA 1) patients.

Who may participate

Age
0 Months – 6 Months
Sex
All
Healthy volunteers
No
Study type
Interventional

Location

  • Peking University, First Hospital, Department of Pediatrics, Beijing, China
  • Bayi Children's Hospital, Seventh Medical Center, PLA general hospital, Beijing, China
  • Shengjing Hospital of China Medical University, Shenyang, China
All listed locations
  • Children's Hospital of Soochow University, Suzhou, China
Key criteria · Original registry text

Inclusion Criteria: * Six months of age and younger on day of vector infusion with Type 1 SAM as defined by the following features: * Diagnosis of SMA based on gene mutation analysis with bi-allelic SMN1 mutations (deletion or point mutations) and 2 copies of SMN2; * Onset of disease before 6 months of age * The patient's legal guardian(s) must be able to understand the purpose and risks of the study and voluntarily provide signed and dated informed consent prior to any study-related procedures being performed. Exclusion Criteria: * Patient who has participated in a previous gene therapy research trials; * Patient who has received Nusinersen and Risdiplam treatment; * Patient who has AAV9 neutralizing antibody titer ≥1:200; * Patient who requires non-invasive ventilatory support averaging≥16 hours/day; * Patient with a point mutation in SMN2 (c.859G\>C); * Patient who requires non-invasive ventilatory support averaging≥16 hours/day at screening; * Patient who use invasive ventilatory support or pulse oximetry \< 95% saturation while awake and calm at screening; * Patient who is positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis C antibody, or treponema pallidum antibody; * Abnormal laboratory values considered clinically significant, including gamma-glutamyl transferase(GGT), Aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin \> 3x upper limit of normal (ULN), Hemoglobin (Hgb)\< 110 or \>150 g/L, platelet \<183x10\^9/L or 614x10\^9/L; * Class IV patient based on Modified Ross Heart Failure Classification for Children; * Patient with a history of glucocorticoid allergy; * Contraindication that would interfere with the lumbar puncture procedures; * Presence of an untreated active infection requiring systemic antiviral therapy at any time during the screening period; * Vaccination less than 2 weeks before infusion of vector; * Patient who has any concurrent clinically significant major disease or any other condition that, in the opinion of the Investigator, makes the subject unsuitable for participation in the study. Note: Other protocol defined inclusion/exclusion criteria may apply.

NCT07943442Recruiting

Novel MRI for an Earlier Diagnosis of Motor Neurone Disease

Motor Neurone Disease (MND) · Health Adult Subjects

Why this research matters

Original registry summary

The goal of the study is Can MR Fingerprinting identify quantitative differences in brains of patients with MND and age-matched healthy controls?

Who may participate

Age
18 Years – Not specified
Sex
All
Healthy volunteers
Yes
Study type
Observational

Location

  • Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom
Key criteria · Original registry text

Inclusion criteria all participants: * ≥18yrs * Able and willing to provide consent * Able to communicate with staff and safely comply with the study procedures Additional inclusion criteria for MND participants: * ALS patients with definite or probable motor neuron disease based on the Awaji criteria Additional inclusion criteria for healthy volunteers: * Free from chronic or current illness particularly: * Neurological disorders including migraines * Psychiatric disorders * Prior head injury resulting in brain damage * Prior neurosurgical or neurovascular intervention * Free from taking medication * Non-drug and non-alcohol abuse * Non-smoker Exclusion criteria all participants: * Contraindication to MRI, including: * non-MRI compatible medical devices and implants * in patients with previous penetrating trauma to the eye, or patients at high risk of previous metal foreign body injury to the eye (e.g. welding), skull x-ray will be performed; these patients may be included in the absence of residual metal fragments on x-ray * Inability to lie flat in the MRI scanner * ALS patients in an advanced disease stage (ALSFRS-R \< 25) with respiratory insufficiency (forced vital capacity (FVC) \< 60%), on non-invasive ventilation or receiving percutaneous gastrostomy feeding. * Pregnant

NCT06841354Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Triple Negative Breast Neoplasms

Why this research matters

Original registry summary

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.

Who may participate

Age
18 Years – Not specified
Sex
All
Healthy volunteers
No
Study type
Interventional

Location

  • USA Mitchell Cancer Institute ( Site 0090), Mobile, Alabama, United States
  • Ironwood Cancer & Research Centers ( Site 0036), Chandler, Arizona, United States
  • City of Hope ( Site 0097), Duarte, California, United States
All listed locations
  • City of Hope Lennar Foundation Cancer Center ( Site 0099), Irvine, California, United States
  • UCLA Department of Medicine - Hematology & Oncology ( Site 0047), Los Angeles, California, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0016), San Francisco, California, United States
  • Yale New Haven Hospital ( Site 0001), New Haven, Connecticut, United States
  • Washington Hospital Center ( Site 0098), Washington D.C., District of Columbia, United States
  • AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0007), Altamonte Springs, Florida, United States
  • Orlando Health Cancer Institute ( Site 0012), Orlando, Florida, United States
  • Florida Cancer Specialists - East ( Site 7000), West Palm Beach, Florida, United States
  • University Cancer & Blood Center, LLC ( Site 0023), Athens, Georgia, United States
  • St. Luke's Cancer Institute: Boise ( Site 0037), Boise, Idaho, United States
  • University of Illinois Cancer Center ( Site 0044), Chicago, Illinois, United States
  • MedStar Franklin Square Medical Center ( Site 0031), Baltimore, Maryland, United States
  • MedStar Good Samaritan Hospital ( Site 0079), Baltimore, Maryland, United States
  • MedStar Southern Maryland Hospital Center ( Site 0100), Clinton, Maryland, United States
  • MedStar Montgomery Medical Center ( Site 0078), Olney, Maryland, United States
  • Holy Cross Hospital ( Site 0091), Silver Spring, Maryland, United States
  • Cancer & Hematology Centers of Western Michigan ( Site 0026), Grand Rapids, Michigan, United States
  • Allina Health Cancer Institute ( Site 0069), Minneapolis, Minnesota, United States
  • Hattiesburg Clinic Hematology/Oncology ( Site 0104), Hattiesburg, Mississippi, United States
  • Comprehensive Cancer Centers of Nevada ( Site 0015), Las Vegas, Nevada, United States
  • Renown Regional Medical Center ( Site 0005), Reno, Nevada, United States
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0082), Hackensack, New Jersey, United States
  • New Mexico Oncology Hematology Consultants Ltd. ( Site 0019), Albuquerque, New Mexico, United States
  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0073), Mineola, New York, United States
  • Laura and Isaac Perlmutter Cancer Center ( Site 0003), New York, New York, United States
  • Rex Hematology Oncology Associates - Garner ( Site 0071), Garner, North Carolina, United States
  • SCRI Oncology Partners ( Site 7004), Nashville, Tennessee, United States
  • Tennessee Oncology ( Site 0018), Nashville, Tennessee, United States
  • Texas Oncology - DFW ( Site 8007), Dallas, Texas, United States
  • Texas Oncology - West Texas ( Site 8004), El Paso, Texas, United States
  • Kelsey-Seybold Clinic - North Houston Campus ( Site 0096), Houston, Texas, United States
  • Kelsey-Seybold Clinic ( Site 0040), Houston, Texas, United States
  • Texas Oncology - San Antonio ( Site 8001), San Antonio, Texas, United States
  • University of Utah, Huntsman Cancer Institute ( Site 0056), Salt Lake City, Utah, United States
  • Virginia Oncology Associates (VOA) ( Site 8002), Norfolk, Virginia, United States
  • Fred Hutchinson Cancer Center ( Site 0042), Seattle, Washington, United States
  • Instituto de Investigaciones Clinicas Mar del Plata ( Site 2401), Mar del Plata, Buenos Aires, Argentina
  • Instituto Alexander Fleming ( Site 2402), Mar del Plata, Buenos Aires, Argentina
  • Hospital Italiano de Cordoba ( Site 2406), Córdoba, Córdoba Province, Argentina
  • Clinica Viedma ( Site 2403), Viedma, Río Negro Province, Argentina
  • Fundacion Estudios Clinicos ( Site 2405), Rosario, Santa Fe Province, Argentina
  • Hospital Provincial del Centenario ( Site 2410), Rosario, Santa Fe Province, Argentina
  • Fundacion Centro Oncologico de Integración Regional ( Site 2400), Mendoza, Argentina
  • Blacktown Hospital ( Site 5500), Blacktown, New South Wales, Australia
  • Peninsula Health Frankston Hospital ( Site 5501), Frankston, Victoria, Australia
  • ZAS Sint Augustinus ( Site 3102), Antwerp, Flanders, Belgium
  • Ziekenhuis Oost Limburg ( Site 3105), Genk, Limburg, Belgium
  • AZ Maria Middelares ( Site 3103), Ghent, Oost-Vlaanderen, Belgium
  • UZ Gent ( Site 3101), Ghent, Oost-Vlaanderen, Belgium
  • Hospital de Câncer de Recife ( Site 2300), Recife, Pernambuco, Brazil
  • Liga Norte Riograndense Contra o Cancer ( Site 2310), Natal, Rio Grande do Norte, Brazil
  • Hospital Nossa Senhora da Conceição ( Site 2302), Porto Alegre, Rio Grande do Sul, Brazil
  • Fundacao Pio XII - Hospital de Cancer de Barretos ( Site 2307), Barretos, São Paulo, Brazil
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 2301), São Jose Do Rio Preto, São Paulo, Brazil
  • IBCC - Núcleo de Pesquisa e Ensino ( Site 2306), São Paulo, Brazil
  • Cross Cancer Institute ( Site 0216), Edmonton, Alberta, Canada
  • Lakeridge Health ( Site 0217), Oshawa, Ontario, Canada
  • North York General Hospital ( Site 0209), Toronto, Ontario, Canada
  • Princess Margaret Cancer Centre ( Site 0202), Toronto, Ontario, Canada
  • CIUSSS- saguenay-Lac-Saint-Jean ( Site 0213), Chicoutimi, Quebec, Canada
  • Centre Hospitalier de l'Université de Montréal ( Site 0208), Montreal, Quebec, Canada
  • Jewish General Hospital ( Site 0203), Montreal, Quebec, Canada
  • St. Marys Hospital Center ( Site 0201), Montreal, Quebec, Canada
  • McGill University Health Centre ( Site 0204), Montreal, Quebec, Canada
  • Hopital Du Saint-Sacrement ( Site 0210), Québec, Quebec, Canada
  • Saskatoon Cancer Centre ( Site 0215), Saskatoon, Saskatchewan, Canada
  • Biocenter ( Site 2009), Concepción, Biobio, Chile
  • IC La Serena Research ( Site 2007), La Serena, Coquimbo Region, Chile
  • Fundación Arturo López Pérez ( Site 2000), Santiago, Region M. de Santiago, Chile
  • Clínica UC San Carlos de Apoquindo ( Site 2008), Santiago, Region M. de Santiago, Chile
  • Bradfordhill ( Site 2001), Santiago, Region M. de Santiago, Chile
  • ONCOCENTRO APYS ( Site 2005), Viña del Mar, Valparaiso, Chile
  • The First Afflilated Hospital of Bengbu Medical College ( Site 5022), Bengbu, Anhui, China
  • The First Affiliated Hospital of Chongqing Medical University ( Site 5039), Chongqing, Chongqing Municipality, China
  • Chongqing University Three Gorges Hospital ( Site 5020), Chongqing, Chongqing Municipality, China
  • The First Affiliated hospital of Xiamen University ( Site 5035), Xiamen, Fujian, China
  • Sun Yat-Sen University Cancer Center ( Site 5014), Guangzhou, Guangdong, China
  • Guangxi Medical University Affiliated Tumor Hospital. ( Site 5008), Nanning, Guangxi, China
  • Henan Cancer Hospital ( Site 5001), Zhengzhou, Henan, China
  • Tongji Hospital Tongji Medical Science & Technology ( Site 5007), Wuhan, Hubei, China
  • Xiangyang Central Hospital ( Site 5017), Xiangyang, Hubei, China
  • Hunan Cancer Hospital ( Site 5002), Changsha, Hunan, China
  • Jiangsu Province Hospital ( Site 5009), Nanjing, Jiangsu, China
  • Xuzhou Central Hospital ( Site 5036), Xuzhou, Jiangsu, China
  • Jilin Province Tumor Hospital ( Site 5040), Changchun, Jilin, China
  • The First Hospital of Jilin University ( Site 5003), Changchun, Jilin, China
  • The First Affiliated Hospital of Xi an Jiaotong University ( Site 5005), Xi'an, Shaanxi, China
  • Jinan Central Hospital ( Site 5031), Jinan, Shandong, China
  • LinYi Cancer Hospital ( Site 5021), Linyi, Shandong, China
  • Shanxi Cancer Hospital ( Site 5043), Taiyuan, Shanxi, China
  • Sichuan Cancer Hospital. ( Site 5018), Chengdu, Sichuan, China
  • The Second People's Hospital of Neijiang ( Site 5016), Neijiang, Sichuan, China
  • Affiliated Tumor Hospital of Xinjiang Medical University ( Site 5006), Ürümqi, Xinjiang, China
  • The First Affiliated Hospital Zhejiang University School of Medicine ( Site 5026), Hangzhou, Zhejiang, China
  • Zhejiang Cancer Hospital ( Site 5012), Hangzhou, Zhejiang, China
  • The Second Affiliated hospital of Zhejiang University school of medicine ( Site 5024), Hangzhou, Zhejiang, China
  • Taizhou Hospital of Zhejiang Province ( Site 5029), Linhai, Zhejiang, China
  • Promotora Médica Las Américas S.A. ( Site 2206), Medellín, Antioquia, Colombia
  • Centro Cancerologico del Caribe LTD ( Site 2209), Barranquilla, Atlántico, Colombia
  • FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 2203), Bogotá, Bogota D.C., Colombia
  • Instituto Nacional de Cancerologia ( Site 2211), Bogotá, Bogota D.C., Colombia
  • IMAT S.A.S ( Site 2202), Montería, Departamento de Córdoba, Colombia
  • Oncologos Del Occidente ( Site 2208), Pereira, Risaralda Department, Colombia
  • Fakultni nemocnice Ostrava ( Site 3505), Ostrava - Poruba, Moravian-Silesian Region, Czechia
  • Vseobecna fakultni nemocnice v Praze ( Site 3501), Prague, Praha 2, Czechia
  • Masarykuv onkologicky ustav ( Site 3500), Brno, South Moravian, Czechia
  • Fakultni nemocnice Olomouc ( Site 3502), Olomouc, Czechia
  • Fakultni Thomayerova nemocnice ( Site 3506), Prague, Czechia
  • Fakultní nemocnice Motol a Homolka ( Site 3503), Prague, Czechia
  • Rigshospitalet University Hospital ( Site 3201), Copenhagen, Capital Region, Denmark
  • Herlev og Gentofte Hospital. ( Site 3205), Copenhagen, Capital Region, Denmark
  • Aarhus Universitets hospital ( Site 3204), Aarhus, Central Jutland, Denmark
  • Odense Universitetshospital ( Site 3202), Odense, Region Syddanmark, Denmark
  • Oulun yliopistollinen sairaala-Oncology and Hematology ( Site 3304), Oulu, North Ostrobothnia, Finland
  • Tampereen yliopistollinen sairaala-Oncology ( Site 3302), Tampere, Pirkanmaa, Finland
  • Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 3301), Helsinki, Uusimaa, Finland
  • CENTRE LEON BERARD ( Site 3004), Lyon, Auvergne-Rhône-Alpes, France
  • Clinique Francois Chenieux ( Site 3006), Limoges, Haute-Vienne, France
  • Institut Regional du Cancer Montpellier ( Site 3009), Montpellier, Herault, France
  • Institut De Cancerologie De L Ouest ( Site 3003), Saint-Herblain, Loire-Atlantique, France
  • Institut Jean Godinot ( Site 3002), Reims, Marne, France
  • Centre Henri Becquerel ( Site 3001), Rouen, Seine-Maritime, France
  • HIA Sainte Anne ( Site 3007), Toulon, Var, France
  • Groupe Hospitalier Paris Saint Joseph ( Site 3010), Paris, France
  • Hôpital Européen Georges Pompidou ( Site 3011), Paris, France
  • Universitatsklinikum Erlangen ( Site 4302), Erlangen, Bavaria, Germany
  • Luisenkrankenhaus Düsseldorf ( Site 4305), Düsseldorf, North Rhine-Westphalia, Germany
  • Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung-Klinik für Senologie/ Brustzentrum ( Site 4304), Essen, North Rhine-Westphalia, Germany
  • Caritas Klinikum Saarbruecken St. Theresia ( Site 4301), Saarbrücken, Saarland, Germany
  • Universitaetsklinikum Leipzig ( Site 4307), Leipzig, Saxony, Germany
  • HELIOS Klinikum Berlin-Buch ( Site 4303), Berlin, Germany
  • Aretaieio Hospital ( Site 3900), Athens, Attica, Greece
  • University General Hospital of Heraklion-Internal Medicine-Oncology ( Site 3903), Heraklion, Irakleio, Greece
  • General University Hospital of Larissa, Oncology Clinic ( Site 3902), Larissa, Thessaly, Greece
  • European Interbalkan Medical Center ( Site 3901), Thessaloniki, Greece
  • Queen Mary Hospital ( Site 6000), Hong Kong, Hong Kong
  • Prince of Wales Hospital ( Site 6001), Hong Kong, Hong Kong
  • Békés Vármegyei Központi Kórház Pándy Kálmán Tagkórház-Megyei Onkológiai Centrum ( Site 3405), Gyula, Bekes County, Hungary
  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Onkoterapias Klinika ( Site 3407), Szeged, Csongrád megye, Hungary
  • Budapesti Uzsoki Utcai Kórház-Onkoradiológiai Osztály ( Site 3408), Budapest, Pest County, Hungary
  • Semmelweis Egyetem-Belgyógyászati és Onkológiai Klinika ( Site 3404), Budapest, Hungary
  • Országos Onkológiai Intézet-B-Belgyógyászati Onkológiai Osztály ( Site 3406), Budapest, Hungary
  • Debreceni Egyetem Klinikai Kozpont ( Site 3411), Debrecen, Hungary
  • Rambam Health Care Campus ( Site 3700), Haifa, Israel
  • Shaare Zedek Medical Center ( Site 3704), Jerusalem, Israel
  • Rabin Medical Center ( Site 3702), Petah Tikva, Israel
  • Sheba Medical Center ( Site 3701), Ramat Gan, Israel
  • Sourasky Medical Center ( Site 3703), Tel Aviv, Israel
  • Humanitas Istituto Clinico Catanese ( Site 4610), Misterbianco, Catania, Italy
  • Istituto Nazionale Tumori Regina Elena ( Site 4607), Rome, Roma, Italy
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 4605), Bologna, Italy
  • Ospedale Policlinico San Martino ( Site 4606), Genova, Italy
  • IRCCS Ospedale San Raffaele ( Site 4600), Milan, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 4601), Milan, Italy
  • Azienda Ospedaliero Universitaria Maggiore della Carità ( Site 4604), Novara, Italy
  • Istituto Oncologico Veneto IRCCS ( Site 4603), Padova, Italy
  • Ospedale Santa Maria della Misericordia ( Site 4611), Perugia, Italy
  • Policlincio Gemelli ( Site 4602), Roma, Italy
  • Aichi Cancer Center ( Site 5117), Nagoya, Aichi-ken, Japan
  • Nagoya City University Hospital ( Site 5108), Nagoya, Aichi-ken, Japan
  • National Cancer Center Hospital East ( Site 5120), Kashiwa, Chiba, Japan
  • National Hospital Organization Shikoku Cancer Center ( Site 5122), Matsuyama, Ehime, Japan
  • Hokkaido University Hospital ( Site 5100), Sapporo, Hokkaido, Japan
  • Kanazawa Medical University Hospital ( Site 5127), Kahoku-gun, Ishikawa-ken, Japan
  • Tokai University Hospital ( Site 5107), Isehara, Kanagawa, Japan
  • St. Marianna University Hospital ( Site 5124), Kawasaki, Kanagawa, Japan
  • Kitasato University Hospital ( Site 5123), Sagamihara, Kanagawa, Japan
  • Kanagawa Cancer Center ( Site 5106), Yokohama, Kanagawa, Japan
  • Mie University Hospital ( Site 5109), Tsu, Mie-ken, Japan
  • Naha Nishi Clinic ( Site 5125), Naha, Okinawa, Japan
  • The University of Osaka Hospital ( Site 5111), Suita, Osaka, Japan
  • Saitama Medical University International Medical Center ( Site 5116), Hidaka, Saitama, Japan
  • Juntendo University Hospital ( Site 5104), Bunkyo, Tokyo, Japan
  • Cancer Institute Hospital of JFCR ( Site 5102), Koto, Tokyo, Japan
  • Toranomon Hospital ( Site 5126), Minato, Tokyo, Japan
  • Showa Medical University Hospital ( Site 5103), Shinagawa, Tokyo, Japan
  • Tokyo Medical University Hospital ( Site 5121), Shinjuku, Tokyo, Japan
  • National Center for Global Health and Medicine ( Site 5105), Shinjuku, Tokyo, Japan
  • Akita University Hospital ( Site 5115), Akita, Japan
  • National Hospital Organization Kyushu Cancer Center ( Site 5119), Fukuoka, Japan
  • Kyushu University Hospital ( Site 5129), Fukuoka, Japan
  • Fukushima Medical University Hospital ( Site 5101), Fukushima, Japan
  • Hiroshima City Hiroshima Citizens Hospital ( Site 5113), Hiroshima, Japan
  • Social medical corporation Hakuaikai Sagara Hospital ( Site 5114), Kagoshima, Japan
  • Kyoto University Hospital ( Site 5110), Kyoto, Japan
  • Okayama University Hospital ( Site 5118), Okayama, Japan
  • Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 5112), Osaka, Japan
  • National Cancer Institute ( Site 5401), Putrajaya, Putrajaya, Malaysia
  • Sarawak General Hospital ( Site 5400), Kuching, Sarawak, Malaysia
  • Pantai Hospital Kuala Lumpur ( Site 5402), Kuala Lumpur, Malaysia
  • University Malaya Medical Centre ( Site 5403), Kuala Lumpur, Malaysia
  • CIO - Centro de Inmuno-Oncología de Occidente ( Site 2504), Guadalajara, Jalisco, Mexico
  • Grupo Médico ASSET SC ( Site 2507), Benito Juárez, Mexico City, Mexico
  • COI Centro Oncologico Internacional S.A.P.I. de C.V. ( Site 2514), Mexico City, Mexico City, Mexico
  • Centro Oncologico de Alta Especialidad, S.C. ( Site 2509), Mexico City, Mexico City, Mexico
  • Higiea Oncologia ( Site 2505), Mexico City, Mexico City, Mexico
  • Filios Alta Medicina ( Site 2506), Monterrey, Nuevo León, Mexico
  • Laboratorio de Patología Clínica del Hospital Universitario "Dr. José Eleuterio González" ( Site 2501), Monterrey, Nuevo León, Mexico
  • Oncare - Unidad Valle ( Site 2502), San Pedro Garza García, Nuevo León, Mexico
  • Centro de Investigacion Clinica de Oaxaca ( Site 2503), Oaxaca City, Oaxaca, Mexico
  • Centro de Investigación Oncológica Galerías SC ( Site 2511), Aguascalientes, Mexico
  • Unidad de Mastologia Avanzada de Chihuahua S.A de C.V ( Site 2510), Chihuahua City, Mexico
  • Centro Potosino de Investigación Médica ( Site 2512), San Luis Potosí City, Mexico
  • Ziekenhuis Rijnstate ( Site 4501), Arnhem, Gelderland, Netherlands
  • Zuyderland Medical Centre ( Site 4507), Sittard Geleen, Limburg, Netherlands
  • ETZ Elisabeth ( Site 4504), Tilburg, North Brabant, Netherlands
  • Deventer Ziekenhuis ( Site 4503), Deventer, Overijssel, Netherlands
  • Erasmus Medisch Centrum ( Site 4505), Rotterdam, South Holland, Netherlands
  • Meander Medisch Centrum ( Site 4500), Amersfoort, Utrecht, Netherlands
  • Martini Ziekenhuis ( Site 4502), Groningen, Netherlands
  • Harbour Cancer & Wellness ( Site 5600), Newmarket, Auckland, New Zealand
  • Bowen Icon Cancer Centre ( Site 5601), Crofton Downs, Wellington Region, New Zealand
  • Clínica Internacional - Sede San Borja ( Site 2604), Lima, Peru
  • IPOR Instituto Peruano de Oncología & Radioterapia ( Site 2601), Lima, Peru
  • Oncosalud ( Site 2600), Lima, Peru
  • Hospital Militar Central Coronel Luis Arias Schereiber ( Site 2603), Lima, Peru
  • Mary Mediatrix Medical Center ( Site 5702), Lipa, Batangas, Philippines
  • Manila Doctors Hospital ( Site 5701), Manila, National Capital Region, Philippines
  • THE MEDICAL CITY ILOILO ( Site 5704), Iloilo City, Philippines
  • Wielkopolskie Centrum Onkologii-Oddział Onkologii Klinicznej i Immunoonkologii z Pododdziałem Dzien ( Site 3811), Poznan, Greater Poland Voivodeship, Poland
  • Centrum Onkologii im prof Franciszka Lukaszczyka ( Site 3802), Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
  • Pratia MCM Krakow ( Site 3812), Krakow, Lesser Poland Voivodeship, Poland
  • Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 3801), Siedlce, Masovian Voivodeship, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Piersi i Chirurgii ( Site 3803), Warsaw, Masovian Voivodeship, Poland
  • Mazowiecki Szpital Onkologiczny ( Site 3807), Wieliszew, Masovian Voivodeship, Poland
  • Bialostockie Centrum Onkologii ( Site 3810), Bialystok, Podlaskie Voivodeship, Poland
  • Szpitale Pomorskie Sp. z o. o. ( Site 3805), Gdynia, Pomeranian Voivodeship, Poland
  • Szpital Wojewodzki im.M.Kopernika. ( Site 3800), Koszalin, West Pomeranian Voivodeship, Poland
  • Institutul Oncologic Cluj ( Site 4701), Cluj-Napoca, Cluj, Romania
  • S.C. Radiotherapy Center Cluj S.R.L ( Site 4705), Comuna Floresti, Cluj, Romania
  • Centrul de Oncologie "Sfântul Nectarie" ( Site 4702), Craiova, Dolj, Romania
  • Spitalul Municipal Schuller Ploiești ( Site 4707), Ploieşti, Prahova, Romania
  • Cabinet Medical Oncomed ( Site 4704), Timișoara, Timiș County, Romania
  • Spitalul Clinic Filantropia ( Site 4703), Bucharest, Romania
  • Centrul Medical Neolife- Baneasa ( Site 4706), Bucharest, Romania
  • National Cancer Center ( Site 5202), Goyang-si, Kyonggi-do, South Korea
  • Seoul National University Bundang Hospital ( Site 5204), Seongnam, Kyonggi-do, South Korea
  • Kyungpook National University Chilgok Hospital ( Site 5205), Daegu, Taegu-Kwangyokshi, South Korea
  • Seoul National University Hospital ( Site 5200), Seoul, South Korea
  • Severance Hospital Yonsei University Health System ( Site 5201), Seoul, South Korea
  • Samsung Medical Center ( Site 5203), Seoul, South Korea
  • HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 4104), Seville, Andalusia, Spain
  • ICO L Hospitalet ( Site 4101), L'Hospitalet de Llobregat, Barcelona, Spain
  • Hospital Clinico San Carlos ( Site 4100), Madrid, Madrid, Comunidad de, Spain
  • Hospital General Universitario de Valencia ( Site 4102), Valencia, Valenciana, Comunitat, Spain
  • Parc de Salut Mar - Hospital del Mar ( Site 4106), Barcelona, Spain
  • Hospital Beata María Ana ( Site 4105), Madrid, Spain
  • Hospital Universitario Ramon y Cajal ( Site 4103), Madrid, Spain
  • Taichung Veterans General Hospital ( Site 5303), Taichung, Taiwan
  • National Cheng Kung University Hospital ( Site 5304), Tainan, Taiwan
  • National Taiwan University Hospital ( Site 5300), Taipei, Taiwan
  • Mackay Memorial Hospital ( Site 5301), Taipei, Taiwan
  • Chang Gung Memorial Hospital ( Site 5302), Taoyuan, Taiwan
  • Faculty of Medicine Siriraj Hospital ( Site 5800), Bangkoknoi, Bangkok, Thailand
  • Songklanagarind hospital ( Site 5801), Hat Yai, Changwat Songkhla, Thailand
  • Faculty of Medicine - Khon Kaen University ( Site 5802), Khon Kaen, Thailand
  • Ege Universitesi Hastanesi ( Site 4803), Bornova, İzmir, Turkey (Türkiye)
  • Adana Medical Park Seyhan Hastanesi ( Site 4804), Adana, Turkey (Türkiye)
  • Hacettepe Universite Hastaneleri ( Site 4800), Ankara, Turkey (Türkiye)
  • Gazi University Health Research and Application Center Gazi Hospital ( Site 4805), Ankara, Turkey (Türkiye)
  • Ankara Bilkent Şehir Hastanesi ( Site 4801), Ankara, Turkey (Türkiye)
  • TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi ( Site 4802), Istanbul, Turkey (Türkiye)
  • Sakarya Egitim Arastirma Hsatanesi ( Site 4809), Sakarya, Turkey (Türkiye)
  • Samsun Medical Park Hastanesi ( Site 4810), Samsun, Turkey (Türkiye)
  • COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 4409), Cherkasy, Cherkasy Oblast, Ukraine
  • Communal Non-Commercial Enterprise Prykarpatski Clinical Oncological Center of Ivano-Frankivsk Regio ( Site 4401), Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine
  • MNE "Khmelnytskyi regional antitumor center" ( Site 4408), Khmelnytskyi, Khmelnytskyi Oblast, Ukraine
  • Ukrainian Center of Tomotherapy ( Site 4400), Kropyvnytskyi, Kirovohrad Oblast, Ukraine
  • Lviv Oncology Regional Treatment and Diagnostic Center ( Site 4407), Lviv, Lviv Oblast, Ukraine
  • ME RIVNE REGIONAL ANTITUMOR CENTER ( Site 4411), Rivne, Rivne Oblast, Ukraine
  • Communal Noncommercial Enterprise "Podillia Regional Oncology Center Of Vinnytsia Regional Council" ( Site 4413), Vinnytsia, Vinnytsia Oblast, Ukraine
  • ME "Volyn Regional Clinical Hospital" of the VRC ( Site 4415), Lutsk, Volyn Oblast, Ukraine
  • Uzhhorod Multispecialty City Clinical Hospital ( Site 4406), Uzhhorod, Zakarpattia Oblast, Ukraine
  • Shalimov Institute of Surgery and Transplantation ( Site 4412), Kyiv, Ukraine
  • Royal Cornwall Hospital ( Site 4003), Truro, Cornwall, United Kingdom
  • St Bartholomew's Hospital ( Site 4001), London, London, City of, United Kingdom
  • University College London Hospital ( Site 4007), London, London, City of, United Kingdom
  • Nottingham University Hospital NHS Trust ( Site 4009), Nottingham, Nottinghamshire, United Kingdom
  • Musgrove Park Hospital ( Site 4005), Taunton, Somerset, United Kingdom
  • Queen Elizabeth Hospital Birmingham ( Site 4017), Birmingham, United Kingdom
  • Velindre Cancer Centre Hospital ( Site 4008), Cardiff, United Kingdom
  • St. James s University Hospital ( Site 4004), Leeds, United Kingdom
Key criteria · Original registry text

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has locally recurrent unresectable or metastatic TNBC that cannot be treated with curative intent * Has not received systemic treatment for locally recurrent unresectable or metastatic breast cancer * Participants previously treated for early-stage breast cancer must have completed all prior therapy for early-stage breast cancer with curative intent at least 6 months before the first disease recurrence * Is a candidate for treatment with pembrolizumab and one of the TPC options: paclitaxel or nab-paclitaxel or gemcitabine + carboplatin * Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline with the exception of alopecia or vitiligo. Participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has breast cancer amenable to treatment with curative intent * Has TNBC with evaluable tumor programmed death ligand 1 (PD-L1) expression at combined positive score (CPS) ≥10 * Has received prior systemic therapy for treatment of locally recurrent unresectable or metastatic breast cancer * Has Grade ≥2 peripheral neuropathy * Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease * Has skin only metastatic disease * Has advanced/metastatic, symptomatic visceral spread at risk of rapidly evolving into life-threatening complications * Human immunodeficiency virus (HIV)-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has known additional malignancy that is progressing or has required active treatment within the past 5 years * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable * Active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed * Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments * Concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV deoxyribonucleic acid (DNA)) and Hepatitis C virus (HCV) (defined as anti-HCV antibody (Ab) positive and detectable HCV ribonucleic acid (RNA)) infection * History of stem cell/solid organ transplant * Has not adequately recovered from major surgery or has ongoing surgical complications

NCT07176286Recruiting

18F-mFBG Cardiac Uptake With Lewy Body Dementia

Parkinson Disease (PD) · Lewy Body Dementia (LBD)

Why this research matters

Original registry summary

This is a Phase 2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of the effect of neurodegenerative diseases on myocardial sympathetic innervation. Effectiveness of 18F-mFBG imaging of the heart will be judged in terms of the quantitative difference between results for subjects with Lewy body and non-Lewy body neurologic disease as compared to historical data for healthy control subjects.

Who may participate

Age
18 Years – Not specified
Sex
All
Healthy volunteers
No
Study type
Interventional

Location

  • Houston Methodist Neurological Institute, Houston, Texas, United States
Key criteria · Original registry text

Inclusion Criteria: * 1\. ≥18 years of age at study entry. 2. Able and willing to comply with study procedures and signed and dated informed consent is obtained. 3\. A male or a female who is either surgically sterile (has had a documented bilateral oophorectomy and/or hysterectomy), postmenopausal (cessation of menses for more than 1 year), non-lactating, or of childbearing potential for whom the result of a serum pregnancy test performed at screening is negative. 4\. All subjects: Judged clinically stable for at least 30 days before enrolment into the study and remains stable to the time of the study imaging procedure. For Lewy body disease subjects (Study Cohort I): 5\. The subject has a diagnosis of either PD or DLB based on accepted clinical criteria at least 6 months before enrollment into the study. For non-Lewy body disease subjects (Study Cohort II): 6\. The subject has a diagnosis of neurological or neurodegenerative disease for which neither PD nor DLB is judged likely by a neurologist based on accepted clinical and imaging criteria. Exclusion Criteria: * 1\. Previously entered into this study or has participated in any other investigational product or medical device study within 30 days of enrollment. 2\. History or suspicion of significant allergic reaction or anaphylaxis to any components of the 18F-mFBG imaging agent. 3\. Presents with any other clinically active, serious, life-threatening disease with a life expectancy of less than 1 year or where participation in the study might compromise the management of the subject or other reason that in the judgment of the investigator(s) makes the subject unsuitable for participation in the study. 4\. Documented ischemic heart disease (prior myocardial infarction, unstable angina, etc) or a diagnosis of heart failure of ischemic or non-ischemic etiology. 5\. Serious non-cardiac medical condition associated with significant elevation of plasma catecholamines including pheochromocytoma. 6\. The subject is claustrophobic or has a movement disorder that prevents him/her from lying still in a supine position for up to 20 minutes. 7\. Renal insufficiency (serum creatinine \>3.0 mg/dL). 8. Uses medications that are known to interfere with uptake of NET-dependent agents and these medications cannot be safely withheld 24 hours before study procedures. 9\. Participated in a research study using ionizing radiation in the previous 12 months such that participation in the study might result in a total effective dose from research procedures exceeding 50 milliSieverts during that time interval.

NCT07758114Recruiting

Prenatal Education on Environmental Exposures During Pregnancy Study (PEEPS)

Environmental Exposure · Pregnancy Related · Preterm Birth · Chronic Respiratory Disease · Neurodegenerative Diseases

Why this research matters

Original registry summary

The purpose of this project is to reduce maternal environmental exposures to toxicants through a patient education program designed to help pregnant women learn about exposure through consumption of contaminated seafood and to be able to use the lessons they learn to have a better understanding of risk.

Who may participate

Age
18 Years – Not specified
Sex
Female
Healthy volunteers
Yes
Study type
Interventional

Location

  • St Vincent's Hope Clinics, Galveston, Texas, United States
  • University of Texas Medical Branch, Galveston, Galveston, Texas, United States
Key criteria · Original registry text

Inclusion Criteria: * Must be at least 18 years old * Must be pregnant, trying, or a mom * Must not have any conditions that would prevent them from carrying out study activities * Must be able to complete surveys and understand instructions Exclusion Criteria: * Participants will not be considered if they are younger than 18 and are not pregnant, trying, or a mom.

NCT05683418Recruiting

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

HR+/HER2-negative Breast Cancer

Why this research matters

Original registry summary

The goal of this clinical trial is to evaluate the safety and efficacy of TOS-358 in women with HR+ HER2- metastatic breast cancer whose tumors have a mutation in PIK3CA and who meet all other study enrollment criteria. The main questions it aims to answer are: 1. Phase 1a: what is the maximum tolerated dose and recommended dose for phase 2? 2. Phase 1a: how safe and tolerable is TOS-358 at different dose levels when taken orally once or twice per day? 3. Phase 1b: how safe and effective is TOS-358 when given with standard of care medicines for HR+HER2- metastatic breast cancer (fulvestrant and CDK4/6i)

Who may participate

Age
18 Years – Not specified
Sex
Female
Healthy volunteers
No
Study type
Interventional

Location

  • University of Southern California Cancer Center, Los Angeles, California, United States
  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
  • Florida Cancer Specialists & Research Institute, St. Petersburg, Florida, United States
All listed locations
  • Northwestern Memorial Hospital, Chicago, Illinois, United States
  • Maryland Oncology Hematology Cancer Specialists, Calverton, Maryland, United States
  • Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States
  • Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
  • Compass Oncology West Cancer Center, Tigard, Oregon, United States
  • University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Sarah Cannon Cancer Center, Nashville, Tennessee, United States
  • Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
  • Texas Oncology - Flower Mound, Flower Mound, Texas, United States
  • MD Anderson Cancer Center, Houston, Texas, United States
  • Virginia Cancer Specialists, Fairfax, Virginia, United States
  • Blue Ridge Cancer Care, Roanoke, Virginia, United States
  • NEXT Oncology - Hospital Quironsalud Barcelona - PPDS, Barcelona, Spain
  • START Barcelona HM Nou Delfos, Barcelona, Spain
  • Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON, Barcelona, Spain
  • Hospital Clinico San Carlos, Madrid, Spain
  • START MADRID Hospital Universitario Fundacion Jimenez Diaz - EDOS, Madrid, Spain
  • START MADRID Hospital Universitario HM Sanchinarro - CIOCC, Madrid, Spain
  • Clinica Universidad de Navarra, Pamplona, Spain
  • NEXT Oncology - Hospital Quironsalud Madrid - PPDS, Pozuelo de Alarcón, Spain
  • Hospital Clinico Universitario de Valencia, Valencia, Spain
Key criteria · Original registry text

Key Inclusion Criteria * Locally advanced, recurrent, or metastatic HR +/HER2- breast cancer * Up to 3 prior lines of therapy for metastatic disease * Willing and able to provide written informed consent for this study * Adults ≥ 18 years old at time of consent * Known PIK3CA mutations or amplifications as determined at a CAP/CLIA-certified or equivalently accredited diagnostic laboratory using a validated test * Measurable or evaluable disease by RECIST 1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy ≥ 6 months, as determined by the investigator * Adequate bone marrow, liver, and kidney function within 14 days prior to first dose of investigational product * Fasting plasma glucose \<= 140 mg/dL AND hemoglobin A1c (HbA1c) \<= 7.0% * Available archived or fresh tumor tissue sample for detection of PIK3CA mutation by central laboratory test Key Exclusion Criteria * Has an established diagnosis of diabetes mellitus type 1 or has uncontrolled diabetes mellitus type 2 * Known active central nervous system (CNS) metastases * PTEN mutations

NCT02446262Recruiting

Neural and Psychological Mechanisms of Pain Perception

Pain · Normal Physiology · Healthy Volunteers

Why this research matters

Original registry summary

Background: \- Painful stimuli cause changes in a network of brain regions called the "Pain Matrix." But most of these regions respond to many other stimuli, not just pain. Researchers want to understand how different factors influence pain. They want to test what happens when people expect different levels of pain and receive treatments that can modify pain. They want to see if these factors influence decisions about pain and how the body responds to it. They also want to compare pain with responses like taste and vision. Objectives: \- To better understand how pain and emotions are processed and influenced by psychological factors. Eligibility: \- Healthy volunteers ages 18-50. Design: * This study requires 1 to 2 clinic visits that last 1 to 3 hours. * Participants will be screened with medical history and physical exam. * Some participants will have one or more magnetic resonance imaging (MRI) scans of their brain. For MRI, participants will lie on a table that slides in and out of a cylinder. The scanner makes loud knocking noises. They will get earplugs. * Participants' heart activity will be recorded with electrocardiogram. Their pulse, sweating, and breathing will be monitored. * Some participants will take a taste test. Others may perform simple tasks. Others may receive pain in their arm, leg, or hand. The pain will come from heat or electric shocks. Others may judge pain using a topical pain-relieving cream. Some of these tests may be given during MRI. * Participants will fill out questionnaires. * The study will last 3 years.

Who may participate

Age
18 Years – 50 Years
Sex
All
Healthy volunteers
Yes
Study type
Interventional

Location

  • National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Key criteria · Original registry text

* INCLUSION CRITERIA: * Healthy * Between 18 and 50 years old * Fluent in English * Able to provide written informed consent. EXCLUSION CRITERIA (all sub-studies): * Unable to comply with study procedures or follow-up visits. * Has a major medical condition or medical history that in a clinician's assessment could affect heat sensitivity, pain thresholds, or ability to comply with study procedures. This may include cardiovascular, autonomic, or neurological conditions, including stroke, blindness, deafness, a history of brain damage, or a chronic systemic disease (e.g., diabetes). * Has a current mood disorder, anxiety disorder, or substance use disorder, or has a history of psychosis, hospitalization for a mental health condition, or recurrent psychiatric episodes. * Has a medical condition that in a clinician's assessment might affect somatosensation (e.g., Raynaud's disease, peripheral neuropathy, or circulatory disorder). * Has a current chronic pain condition or has had chronic pain in the past (painful condition lasting more than six months). * Has a dermatological condition affecting the testing region such as scars, burns, or recent tattoos that might influence cutaneous sensibility. * Regular use of prescription medication that has a significant effect on pain or heat perception. Excluded medications include central-acting agents such as opiates (morphine, tramadol), antidepressants (amitriptyline, duloxetine, milnacipran), anticonvulsants (gabapentin, pregabalin), anxiolytics (barbituates, benzodiazepines), hypnotics (zolpidem, sodium oxybate), antipsychotics (valproate, lithium, olanzapine), antimigraine agents (sumatriptan, ergotamine), and muscle relaxants (cyclobenzaprine, carisoprodol). Use of analgesic medications, such as non-steroidal anti-inflammatories, salicylates, and acetaminophen, taken on an "as needed" basis is acceptable as long as the last dose taken was within 5 half-lives of testing. * Is pregnant. * NIH staff member who is a subordinate/relative/co-worker of any investigator on the protocol. EXCLUSION CRITERIA (fMRI sub-studies): * Individuals with conditions that could pose a risk relating to the safety of the fMRI procedure or pain stimulation will be excluded from the MRI portion of the protocol, but may participate in the non-fMRI sessions (with the exception of pregnant women). Such conditions include: * Those with ferromagnetic metal in the cranial cavity or eye, e.g. aneurysm clip, implanted neural stimulator, cochlear implant, ocular foreign body. * Those with an abnormality on a structural MRI. * Those with an implanted cardiac pacemaker or auto-defibrillator. * Those with an insulin pump. * Those with irremovable body piercing. * Pregnant women (based on urine test completed within 24 hours prior to scan). * Individuals who are left-handed (based on self-report or score on handedness questionnaire) will be excluded from fMRI substudies. EXCLUSION CRITERIA (placebo analgesia sub-studies): -Participation in an NIH study of analgesia, as gleaned from CRIS.

NCT07721025Recruiting

Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy

Friedreich Ataxia · Cardiomyopathy, Secondary

Why this research matters

Original registry summary

The purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy in participants with Friedreich ataxia (FA) cardiomyopathy (CM).

Who may participate

Age
6 Years – Not specified
Sex
All
Healthy volunteers
No
Study type
Interventional

Location

  • Arkansas Children's, Little Rock, Arkansas, United States
  • University of California San Diego, La Jolla, California, United States
  • Ataxia Center and HD Center of Excellence (UCLA), Los Angeles, California, United States
All listed locations
  • University of South Florida, Tampa, Florida, United States
  • Indiana University, Indianapolis, Indiana, United States
  • Boston Children's Hospital, Boston, Massachusetts, United States
  • Mayo Clinic, Rochester, Minnesota, United States
  • Washington University School of Medicine, St Louis, Missouri, United States
  • Cincinnati Children's Hospital, Cincinnati, Ohio, United States
  • Hospital Universitário Walter Cantídio - Universidade Federal do Ceará, Fortaleza, Ceará, Brazil
  • Instituto D'Or de Pesquisa e Ensino - Hospital São Rafael, Salvador, Estado de Bahia, Brazil
  • Hospital das Clínicas da Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil
  • Campinas State University (UNICAMP), Campinas, São Paulo, Brazil
  • UPC Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil
  • Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada
  • Motol University Hospital and the Second Faculty of Medicine, Prague, Czechia
  • Institut de Cardiologie, Hôpital Pitié-Salpêtrière, Paris, France
  • University Hospital Tübingen, Department of Neurology, Tübingen, Baden-Wurttemberg, Germany
  • Federico II University, Naples, Italy, Italy
  • Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain
  • St. Bartholomew's Hospital, London, United Kingdom
  • Imperial College Healthcare NHS Trust, London, United Kingdom
Key criteria · Original registry text

Inclusion Criteria: * Male or female, age at least 6 years at the time of signing the informed consent (and assent, if applicable). * Diagnosis of FA, based on clinical phenotype and genotype (GAA expansion on the frataxin gene) * Onset of FA on or before 25 years of age * Confirmed left ventricular hypertrophy and abnormal left ventricular mass index * Left ventricular ejection fraction at least 30% * Anti-AAVrh.10 total antibody titer less than the protocol-specified maximum level Exclusion Criteria: * Presence of other forms of cardiomyopathy that contribute to heart failure * Current use of inotrope infusion or presence of a ventricular assist device * Contraindication to cardiac MRI * Prior organ transplant * Previous gene transfer or cell therapy * Poorly controlled diabetes (hemoglobin A1c ≥8%) * Active hematologic or solid organ cancer Other inclusion/exclusion criteria to be applied as per protocol.

NCT07943702Recruiting

Correlation Between Visual Reading and DOlab Software Quantitative Analysis of DaT-SPECT Images

Parkinsonian Disorders · Parkinson Disease · Lewy Body Disease · Movement Disorders

Why this research matters

Original registry summary

The goal of this study is to find out whether the quantitative results of DOlab software (DaT-SPECT workflow) agree with the visual reading of brain scans performed by nuclear medicine physicians. The scans are 123I-ioflupane DaT-SPECT images of adults who were evaluated for dopamine transporter dysfunction, a condition seen in Parkinson's disease, other parkinsonian syndromes and dementia with Lewy bodies. The main questions it aims to answer are: * Do the visual scores given by expert readers (0 = normal to 3 = marked abnormality) correlate with the values calculated by the software? * Does using the software report change or refine the readers' classification compared with visual reading alone? * How usable do readers find the software? The study uses existing scans of 120 patients collected between January 2015 and May 2025 at two Italian hospitals. No new tests or treatments are given to participants, and the software results are not used for their clinical care.

Who may participate

Age
18 Years – Not specified
Sex
All
Healthy volunteers
No
Study type
Observational

Location

  • Azienda USL Toscana Centro - Ospedale Santo Stefano, Prato, Tuscany, Italy
  • Azienda Ospedale Università Padova, Padova, Veneto, Italy
Key criteria · Original registry text

Inclusion Criteria: * Age 18 years or older. * Referred for evaluation of nigrostriatal dopaminergic dysfunction to one of the participating centers between January 2015 and May 2025. * Informed consent for data collection, or documentation that all reasonable efforts to obtain consent were made (Italian Privacy Code, art. 110). * 123I-ioflupane SPECT images that: * were acquired according to the PPMI imaging protocol; * have a field of view covering the entire head, from the superior cortical regions to the lower cerebellum; * followed the radiotracer manufacturer's acquisition timing and methods; * were attenuation-corrected according to local standard procedures. Exclusion Criteria: * Age under 18 years. * Use of drugs or substances that may significantly affect DaT binding (e.g., cocaine, amphetamines, CNS stimulants, opioid derivatives, antidepressants, adrenergic agonists, anticholinergics, anesthetics) without a washout of at least five biological half-lives before DaT-SPECT, per the EANM/SNMMI guidelines. * DaT-SPECT performed outside the January 2015 - May 2025 period. * Images not meeting the acquisition and quality specifications listed above.

NCT06014424Recruiting

Cannabidiol Medication Intervention Trial

Alzheimer Disease

Why this research matters

Original registry summary

CALM-IT is a Randomized, double-blind, placebo-controlled cross-over clinical trial. Safety and efficacy of cannabidiol (CBD) capsules assessed for managing agitation in patients with AD and to identify novel biomarkers of agitation severity and treatment response.

Who may participate

Age
55 Years – Not specified
Sex
All
Healthy volunteers
No
Study type
Interventional

Location

  • University of Calgary, Calgary, Alberta, Canada
  • London Health Sciences Centre, London, Ontario, Canada
  • Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
All listed locations
  • Centre for Addiction and Mental Health, Toronto, Ontario, Canada
  • Ontario Shores Centre for Mental Health Sciences, Whitby, Ontario, Canada
Key criteria · Original registry text

Inclusion Criteria: 1. Males or females ≥55 years of age; female must be post-menopausal or must agree to comply with contraception requirements. Males should also abide by contraceptive requirements when the partner is a woman of childbearing potential. Acceptable methods of contraception include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, which may be oral, intravaginal, or transdermal; progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injectable, or implantable; intrauterine device or intrauterine hormone-releasing system; vasectomy of a female participant's male partner (with medical assessment and confirmation of vasectomy surgical success); bilateral tubal occlusion 2. Diagnostic and Statistical Manual of Mental Disorders-5 (DSM 5) criteria for Major Neurocognitive Disorder due to possible AD. Patients with Major Neurocognitive Disorder due to multiple etiologies (AD and vascular) will be included 3. Presence of clinically significant agitation based on the IPA definition at both screening and baseline 4. If treated with cognitive-enhancing medications (cholinesterase inhibitors and/or memantine), dosage must be stable for at least 3 months prior to study randomization 5. Availability of a primary caregiver to accompany the participant to study visits and to participate in the study. The primary caregiver must be sufficiently proficient in English to complete the required study assessments, as per investigator judgement and should spend at least 10 hours a week with the participant 6. Willing and able to provide informed consent and/or have a Substitute Decision Maker (SDM) provide informed consent on behalf of the participant Exclusion Criteria: 1. Change in psychotropic medications less than the duration of 5 half-lives of the medication in question prior to screening (e.g., concomitant antidepressants or atypical antipsychotics) and any changes during study participation 2. Contraindications to CBs, e.g. allergies to cannabis and cannabis products, potential clinically important drug-drug interactions (e.g. strong CYP3A4 inducers/inhibitors, anticonvulsants) 3. Uncontrolled vascular disease, clinically important cerebrovascular disease or current uncontrolled cardiovascular disease (e.g. uncontrolled hypertension, ischemic heart disease, arrhythmia and severe heart failure, cardiovascular accident in the 3 months prior to Screening (V1)), as per investigator assessment 4. Clinically significant liver disease, (e.g., serum alanine aminotransferase or aspartate aminotransferase \> 2 x upper limit of normal (ULN), or total bilirubin \> 1.5 x ULN) collected within one more of or at screening. The Investigator may decide to repeat the assessment to confirm clinical significance prior to screen failing the participant 5. Clinically significant impaired renal function at screening, as per investigator assessment 6. Currently meeting DSM 5 criteria for Major Depressive Episode Presence, or current substance dependence (excluding caffeine and nicotine) or history of other major psychiatric disorders or neurological conditions (e.g. psychotic disorders, schizophrenia, stroke, epilepsy) 7. Clinically significant delusions and/or hallucinations (e.g. NPI-NH delusion/hallucinations subscore ≥4 or judgement of QI) 8. Reported use of marijuana or cannabinoid-based medications, products or supplements (botanical or synthetic) within 1 week prior to randomization 9. Systolic blood pressure (SBP) \< 90 mmHg or \> 150 mmHg or diastolic blood pressure (DBP) \< 50mmHg or \> 105 mmHg at screening or baseline (prior to randomization)

NCT07430956Recruiting

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

Atrial Fibrillation (AF)

Why this research matters

Original registry summary

This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. When this happens, blood cannot move smoothly through the heart; it can slow down or pool in one spot, which can lead to the formation of blood clots. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how effective and safe REGN7508 and REGN9933, individually, are in preventing ischemic stroke or systemic embolism in people with atrial fibrillation who cannot or may choose to not take blood thinners. The study is looking at several other research questions, including: * What side effects may happen from taking REGN7508 or REGN9933 * How well does REGN7508 or REGN9933 lower the risk of having an ischemic stroke and/or systemic embolism compared to the placebo * How well does REGN7508 or REGN9933 lower the risk of having a major health problem affecting heart and blood circulation compared to placebo * How well does REGN7508 or REGN9933 lower the risk of death compared to placebo * How much REGN7508 or REGN9933 is in the blood at different times * Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the study drugs less effective or could lead to side effects)

Who may participate

Age
18 Years – Not specified
Sex
All
Healthy volunteers
No
Study type
Interventional

Location

  • SEC Clinical Research, Dothan, Alabama, United States
  • Sun City Clinical Research, Glendale, Arizona, United States
  • Arkansas Cardiology P.A., Little Rock, Arkansas, United States
All listed locations
  • Mission Cardiovascular Research Institute, Fremont, California, United States
  • National Institute of California Heart and Vein Specialists, Huntington Beach, California, United States
  • Profound Research LLC at San Diego Cardiovascular Associates, La Jolla, California, United States
  • Valley Clinical Trials, LLC dba Flourish Research, Northridge, California, United States
  • Profound Research LLC at Southern California Heart Specialists, Pasadena, California, United States
  • FOMAT - Comprehensive Cardiovascular Care, Santa Maria, California, United States
  • Cardiology Associates Medical Group, Ventura, California, United States
  • Interventional Cardiology Medical Group, West Hills, California, United States
  • East Coast Institute for Research, Jacksonville, Jacksonville, Florida, United States
  • South Florida Research Organization LLC, Medley, Florida, United States
  • Sec Clinical Research, Pensacola, Florida, United States
  • Cardiovascular Center of Sarasota Foundation for Research and Education, Sarasota, Florida, United States
  • Clinical Site Partners, LLC DBA Flourish Research, Winter Park, Florida, United States
  • Atlanta Clinical Research Centers, Atlanta, Georgia, United States
  • NSC Research, Inc, Johns Creek, Georgia, United States
  • Franciscan Physician Network, Indiana Heart Physicians, Indianapolis, Indiana, United States
  • Indiana Medical Research, Merrillville, Indiana, United States
  • Profound Research, Powers Health Medical Group - Electrophysiology, Munster, Indiana, United States
  • Monroe Research, LLC, West Monroe, Louisiana, United States
  • Profound Research, Cardiology and Vascular Associates (CAVA) - Bloomfield Hills, Bloomfield Hills, Michigan, United States
  • Profound Research, Millennium Cardiology, Farmington Hills, Michigan, United States
  • Flint Clinical Research, Flint, Michigan, United States
  • AA Medical Research Center (MRC), Flint, Michigan, United States
  • Jackson Heart Clinic, Jackson, Mississippi, United States
  • Olive Branch Family Medical Center, Olive Branch, Mississippi, United States
  • Super Health Pharmacy, Staten Island, New York, United States
  • Hawthorne Health, Moose Pharmacy of Concord, Concord, North Carolina, United States
  • K&R Research LLC, Marion, Ohio, United States
  • AnMed Health, Anderson, South Carolina, United States
  • Monument Health Clinical Research, Rapid City, South Dakota, United States
  • Tennessee Center for Clinical Trials, Tullahoma, Tennessee, United States
  • PharmaTex Research, Amarillo, Texas, United States
  • PanAmerican Clinical Research, Brownsville, Texas, United States
  • Southwest Family Medicine Associates, Dallas, Texas, United States
  • East Texas Cardiology, Houston, Texas, United States
  • Synergy Group Medical,LLC, Houston, Texas, United States
  • Synergy Groups Medical, Houston, Texas, United States
  • Heart Institute of East Texas, Lufkin, Texas, United States
  • Texas Institute of Cardiology PA, McKinney, Texas, United States
  • Synergy Group Medical, LLC, Missouri City, Texas, United States
  • Conquest Research, Vienna, Virginia, United States
  • Hamilton Medical Research Group (HMRG), Hamilton, Ontario, Canada
Key criteria · Original registry text

Key Inclusion Criteria: 1. Has AF or flutter (paroxysmal or persistent), not considered to be secondary to a reversible cause 2. At moderate to high risk for stroke defined as: 1. CHA2DS2-VA \[C: Congestive heart failure; H: Hypertension; A2: Age ≥75 years (double points); D: Diabetes mellitus; S2: Stroke or TIA or Systemic embolism (double points); V: Vascular disease; A: Age 65-74 years\] score ≥4 OR 2. CHA2DS2-VA score of 3 AND at least 1 enrichment criteria as described in the protocol 3. Shared decision making between the participant and provider determining that the bleeding risk of Oral Anticoagulant (OAC) therapy outweighs the benefits, making the participant unsuitable for OAC therapy as described in the protocol Key Exclusion Criteria: 1. Has a mechanical heart valve prosthesis (Note: transcatheter aortic valve replacement is not an exclusion) 2. Had an ischemic stroke within 2 days prior to randomization 3. Has persistent, uncontrolled hypertension (per investigator's discretion) 4. Has a history of Central Nervous System (CNS) bleeding within 30 days prior to randomization 5. Has a life expectancy less than 12 months 6. Has participated in a prior Factor XI (FXI) inhibitor study Note: Other protocol-defined Inclusion/ Exclusion criteria apply

NCT06976216Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

Alzheimer's Disease

Why this research matters

Original registry summary

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

Who may participate

Age
60 Years – 85 Years
Sex
All
Healthy volunteers
No
Study type
Interventional

Location

  • Healthy Brain Clinic, Long Beach, California, United States
  • Anderson Clinical Research, Redlands, California, United States
  • Mountain Neurological Research Center, Basalt, Colorado, United States
All listed locations
  • Georgetown University Medical Center, Washington D.C., District of Columbia, United States
  • JEM Research Institute, Atlantis, Florida, United States
  • VIN-Julie Schwartzbard, Aventura, Florida, United States
  • Merritt Island Medical Research, LLC, Merritt Island, Florida, United States
  • Renstar Medical Research, Ocala, Florida, United States
  • Alzheimer's Research and Treatment Center, Stuart, Florida, United States
  • Charter Research - Lady Lake, The Villages, Florida, United States
  • Local Institution - 0016, Columbus, Georgia, United States
  • Center for Advanced Research & Education, Gainesville, Georgia, United States
  • Re:Cognition Health - Chicago, Chicago, Illinois, United States
  • Ascension Alexian Brothers, Elk Grove Village, Illinois, United States
  • Boston Center for Memory, Newton, Massachusetts, United States
  • HealthPartners Neuroscience Center, Saint Paul, Minnesota, United States
  • Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States
  • NYU Langone Health, New York, New York, United States
  • Local Institution - 0259, New York, New York, United States
  • SUNY Upstate Medical University, Syracuse, New York, United States
  • Local Institution - 0007, Matthews, North Carolina, United States
  • Ohio State University, Columbus, Ohio, United States
  • NDx Clinical Research Inc., Dayton, Ohio, United States
  • Summit Headlands, Portland, Oregon, United States
  • Local Institution - 0004, Abington, Pennsylvania, United States
  • Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States
  • Neurology Clinic, P.C., Cordova, Tennessee, United States
  • Gadolin Research, Beaumont, Texas, United States
  • Fundación para el Estudio y Tratamiento de Enfermedades Mentales (FETEM), Buenos Aires, Buenos Aires F.D., Argentina
  • Local Institution - 0271, Buenos Aires, Argentina
  • Fundación Lennox - Instituto Modelo de Neurología, Córdoba, Argentina
  • Sanatorio Morra S.A., Córdoba, Argentina
  • Instituto Kremer, Córdoba, Argentina
  • Southern Neurology, Kogarah, New South Wales, Australia
  • KARA Institute for Neurological Diseases, Macquarie Park, New South Wales, Australia
  • NeuroCentrix, Carlton, Victoria, Australia
  • Neurodegenerative Disorders Research, Perth, Western Australia, Australia
  • St Vincent's Hospital Sydney Limited, Darlinghurst, Australia
  • L2IP - Instituto de Pesquisas Clínicas, Brasília, Federal District, Brazil
  • Instituto de Neurologia de Curitiba, Curitiba, Paraná, Brazil
  • Local Institution - 0266, Aracaju, Sergipe, Brazil
  • Hospital das Clinicas FMUSP, São Paulo, Brazil
  • OCT Research ULC, Kelowna, British Columbia, Canada
  • Richmond Clinical Trials, Richmond, British Columbia, Canada
  • Centricity Research Halifax Multispecialty, Halifax, Nova Scotia, Canada
  • Ottawa Memory Clinic, Ottawa, Ontario, Canada
  • Toronto Memory Program, Toronto, Ontario, Canada
  • MoCA Research and Innovation Inc., Greenfield Park, Quebec, Canada
  • Diex Recherche Victoriaville, Victoriaville, Quebec, Canada
  • ALPHA Recherche Clinique, Québec, Canada
  • Local Institution - 0094, Santiago, Santiago Metropolitan, Chile
  • Especialidades Médicas LYS, Santiago, Santiago Metropolitan, Chile
  • Local Institution - 0241, Santiago, Santiago Metropolitan, Chile
  • Local Institution - 0230, Antofagasta, Chile
  • Local Institution - 0215, Zagreb, City of Zagreb, Croatia
  • Poliklinika Neuron, Zagreb, City of Zagreb, Croatia
  • Klinika za psihijatriju "Vrapče", Zagreb, Croatia
  • Neuro Health Centrum, Brno, Brno-město, Czechia
  • AGE Centrum, Olomouc, Olomouc Region, Czechia
  • A-Shine, Pilsen, Plzeň-město, Czechia
  • Neurologická Ambulance - Forbeli, Prague, Praha 6, Czechia
  • Neuropsychiatrie, Prague, Praha 6, Czechia
  • Institut neuropsychiatricke pece (INEP), Praha, Prague, Praha 8, Czechia
  • Vestra Clinics, Rychnov nad Kněžnou, Czechia
  • Local Institution - 0295, Nice, Alpes-Maritimes, France
  • Local Institution - 0289, Toulouse, Haute-Garonne, France
  • Local Institution - 0290, Rouen, Haute-Normandie, France
  • Local Institution - 0291, Montpellier, Languedoc-Roussillon, France
  • Local Institution - 0299, Reims, Marne, France
  • Hôpital des Charpennes - Hospices Civils de Lyon (HCL), Villeurbanne, Rhône, France
  • Local Institution - 0294, Dijon, France
  • Local Institution - 0301, Mannheim, Baden-Wurttemberg, Germany
  • Universitätsklinikum Münster - Albert Schweitzer Campus, Münster, North Rhine-Westphalia, Germany
  • Universitätsmedizin Johannes Gutenberg Universität Mainz, Mainz, Rhineland-Palatinate, Germany
  • Charite-Universitaetsmedizin Berlin - Campus Benjamin Franklin (CBF), Berlin, State of Berlin, Germany
  • Local Institution - 0300, Aachen, Germany
  • Local Institution - 0302, Berlin, Germany
  • Local Institution - 0277, Bremen, Germany
  • Local Institution - 0275, Hamburg, Germany
  • TUM Klinikum, Munich, Germany
  • University General Hospital of Alexandroupoli, Alexandroupoli, Anatolikí Makedonía Kai Thráki, Greece
  • Local Institution - 0256, Athens, Attikí, Greece
  • Aiginiteio University Hospital, Athens, Attikí, Greece
  • University General Hospital of Larissa, Larissa, Thessalía, Greece
  • Local Institution - 0288, Bengaluru, Karnataka, India
  • Local Institution - 0282, Hyderabad, Telangana, India
  • Local Institution - 0285, Hyderabad, Telangana, India
  • Local Institution - 0287, Varanasi, Uttar Pradesh, India
  • Local Institution - 0286, Kolkata, West Bengal, India
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Lombardy, Italy
  • Ospedale San Raffaele, Milan, Lombardy, Italy
  • Fondazione IRCCS San Gerardo dei Tintori, Monza, Lombardy, Italy
  • Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy
  • Brain Research Center Den Bosch B.V., 's-Hertogenbosch, North Brabant, Netherlands
  • Local Institution - 0297, Amsterdam, North Holland, Netherlands
  • Brain Research Center Zwolle, Zwolle, Overijssel, Netherlands
  • Centrum Medyczne HCP, Poznan, Greater Poland Voivodeship, Poland
  • Osrodek Badan Klinicznych CLINSANTE S.C., Torun, Kuyavian-Pomeranian Voivodeship, Poland
  • MlynowaMed Psychiatric, Bialystok, Podlaskie Voivodeship, Poland
  • Penta Hospitals Badania Kliniczne - Gdańsk 1, Gdansk, Pomeranian Voivodeship, Poland
  • Instituto De Neurologia Dra. Ivonne Fraga, San Juan, Puerto Rico
  • Prof. Dr. Alexandru Obregia Psychiatry Hospital, Bucharest, Bucharest, Romania
  • Prof. Dr. Alexandru Obregia Psychiatry Hospital, Bucharest, Bucharest, Romania
  • Institutul Național de Gerontologie și Geriatrie "Ana Aslan", Bucharest, Romania
  • Centrul de Sanatate Mintala, Bucharest, Romania
  • Institutul de Psihiatrie Socola, Iași, Romania
  • Chonnam National University Hospital, Gwangju, Kwangju-Kwangyǒkshi, South Korea
  • Seoul National University Bundang Hospital, Seongnam, Kyǒnggi-do, South Korea
  • Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [Seoul], South Korea
  • Hanyang University Seoul Hospital, Seoul, Seoul-teukbyeolsi [Seoul], South Korea
  • Konkuk University Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], South Korea
  • Samsung Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], South Korea
  • Ewha Womans University Seoul Hospital, Seoul, Seoul-teukbyeolsi [Seoul], South Korea
  • Hospital Victoria Eugenia, Seville, Andalusia, Spain
  • Hospital Universitari General de Catalunya, Sant Cugat del Vallès, Barcelona [Barcelona], Spain
  • Hospital Clínic de Barcelona, Barcelona, Catalunya [Cataluña], Spain
  • Hospital Universitari de Santa Maria, Lleida, Lleida [Lérida], Spain
  • Clinica Universidad de Navarra, Pamplona, Navarre, Spain
  • Hospital Clinico San Carlos, Madrid, Spain
Key criteria · Original registry text

Inclusion Criteria * Participants must have a confirmed diagnosis of Alzheimer's disease (AD), specifically at the mild (stage 4) or moderate (stage 5) dementia stages, as defined by the National Institute on Aging and Alzheimer's Association (NIA-AA) core clinical criteria. The diagnosis of AD pathology must be confirmed through the 2024 revised NIA-AA Workgroup criteria using a stepwise diagnostic approach. * Participants must have an Mini-Mental State Examination (MMSE) score ranging from 12 through 22, inclusive, at the time of screening. * Participants must have a designated caregiver who maintains adequate contact (around 10 hours per week or more) and is willing to attend all study visits. The caregiver must also be responsible for reporting on the participant's condition, overseeing medication compliance, and consenting to their involvement in both their own and the participant's study-related activities. * Participants on acetyl choline esterase inhibitors (AChEIs) and/or memantine, must have been on a stable dosage for at least 12 weeks prior to screening, and agree to maintain this stable dose for the study duration. Exclusion Criteria * Participants must not present with any significant or severe medical conditions that could compromise their safety, the ability to comply with or complete the study, or the integrity of the study results. This includes any grade of hepatic impairment, urinary retention, active biliary disease, moderate-severe renal impairment (eGFR of \<50 mL/min), and unstable hypertension or tachycardia. * Participants must not have any primary psychiatric diagnoses such as major depression, schizoaffective disorder, or bipolar disorder, and those with severe psychiatric symptoms that could complicate the interpretation of treatment effects, impair cognitive assessment, or impact study completion. * Participants must not have a history of schizophrenia or other chronic psychosis, as well as those who have previously been exposed to KarXT or are currently undergoing treatment with disease-modifying anti-amyloid therapies for AD within the past 6 months prior to screening. * Participants must not have significant pathological findings on brain magnetic resonance imaging (MRI) at screening that reflect significant pathology other than AD or could affect safety or interfere with study procedures. * Other protocol-defined Inclusion/Exclusion criteria apply.

NCT06952504Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Endometrial Cancer

Why this research matters

Original registry summary

Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cells * Advanced means the cancer has spread locally or to other parts of the body (metastatic) and cannot be removed with surgery * Recurrent means the cancer came back after surgery Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study medicines. Sac-TMT is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goal of this study is to learn if people who receive sac-TMT with pembrolizumab live longer and without the cancer getting worse compared to people who receive pembrolizumab alone.

Who may participate

Age
18 Years – Not specified
Sex
Female
Healthy volunteers
No
Study type
Interventional

Location

  • University of South Alabama, Mitchell Cancer Institute ( Site 6033), Mobile, Alabama, United States
  • Alaska Women's Cancer Care ( Site 6036), Anchorage, Alaska, United States
  • CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 5014), Irvine, California, United States
All listed locations
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 6020), Orange, California, United States
  • Sansum Clinic (Ridley Tree) ( Site 8007), Solvang, California, United States
  • John Muir Health Cancer Center ( Site 6028), Walnut Creek, California, United States
  • Yale University School of Medicine ( Site 6009), New Haven, Connecticut, United States
  • MedStar Washington Hospital Center ( Site 5005), Washington D.C., District of Columbia, United States
  • Florida Cancer Specialists - South ( Site 7003), Fort Myers, Florida, United States
  • UF Health Davis Cancer Pavilion and Shands Med Plaza ( Site 6026), Gainesville, Florida, United States
  • Mount Sinai Braman Comprehensive Cancer Center ( Site 6031), Miami Beach, Florida, United States
  • AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002), Orlando, Florida, United States
  • Florida Cancer Specialists ( Site 7002), St. Petersburg, Florida, United States
  • Florida Cancer Specialists East ( Site 7001), West Palm Beach, Florida, United States
  • St. Joseph's/Candler Health System ( Site 6021), Savannah, Georgia, United States
  • University of Chicago Medical Center ( Site 5002), Chicago, Illinois, United States
  • Parkview Research Center ( Site 6008), Fort Wayne, Indiana, United States
  • Women's Cancer Care ( Site 6010), Covington, Louisiana, United States
  • TRIALS 365 ( Site 6005), Shreveport, Louisiana, United States
  • Maine Medical Center - Scarborough Campus ( Site 6042), Scarborough, Maine, United States
  • Tufts Medical Center ( Site 6052), Boston, Massachusetts, United States
  • Minnesota Oncology Hematology, PA ( Site 8003), Minneapolis, Minnesota, United States
  • St. Dominic's Hospital ( Site 5004), Jackson, Mississippi, United States
  • Washington University - School of Medicine ( Site 5006), St Louis, Missouri, United States
  • The Center of Hope ( Site 5018), Reno, Nevada, United States
  • Holy Name Medical Center ( Site 6011), Teaneck, New Jersey, United States
  • University of New Mexico Comprehensive Cancer Center ( Site 6046), Albuquerque, New Mexico, United States
  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 6055), Mineola, New York, United States
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6004), New York, New York, United States
  • Memorial Sloan Kettering Cancer Center ( Site 6053), New York, New York, United States
  • Duke Cancer Institute ( Site 6049), Durham, North Carolina, United States
  • FirstHealth of the Carolinas ( Site 6037), Pinehurst, North Carolina, United States
  • Miami Valley Hospital South ( Site 6014), Centerville, Ohio, United States
  • University of Cincinnati Medical Center ( Site 5013), Cincinnati, Ohio, United States
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007), Columbus, Ohio, United States
  • Kettering Health Main Campus-Kettering Health Cancer Center ( Site 5001), Kettering, Ohio, United States
  • University of Oklahoma Health Sciences Center, Stephenson Cancer Center ( Site 6012), Oklahoma City, Oklahoma, United States
  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 6047), Tulsa, Oklahoma, United States
  • Oncology Associates of Oregon, P.C. ( Site 8005), Eugene, Oregon, United States
  • St. Luke's University Health Network ( Site 6041), Bethlehem, Pennsylvania, United States
  • Hospital of the University of Pennsylvania ( Site 5007), Philadelphia, Pennsylvania, United States
  • Hospital of the University of Pennsylvania ( Site 6023), Philadelphia, Pennsylvania, United States
  • AHN West Penn Hospital ( Site 6006), Pittsburgh, Pennsylvania, United States
  • Women & Infants Hospital ( Site 5003), Providence, Rhode Island, United States
  • Erlanger Medical Center ( Site 5009), Chattanooga, Tennessee, United States
  • Texas Oncology - DFW ( Site 8004), Fort Worth, Texas, United States
  • Houston Methodist Hospital ( Site 6057), Houston, Texas, United States
  • Texas Oncology-San Antonio Medical Center ( Site 8001), San Antonio, Texas, United States
  • Texas Oncology - Northeast Texas ( Site 8002), Tyler, Texas, United States
  • Texas Oncology - Gulf Coast ( Site 8006), Webster, Texas, United States
  • Inova Schar Cancer Institute ( Site 6003), Fairfax, Virginia, United States
  • Virginia Cancer Specialists (VCS) ( Site 8008), Fairfax, Virginia, United States
  • VCU Health Adult Outpatient Pavillion ( Site 5000), Richmond, Virginia, United States
  • Instituto Alexander Fleming ( Site 0105), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0108), Mar del Plata, Buenos Aires, Argentina
  • Fundación Respirar ( Site 0101), Buenos Aires, Buenos Aires F.D., Argentina
  • Hospital Británico de Buenos Aires ( Site 0103), CABA, Argentina
  • Instituto San Marcos ( Site 0106), San Juan, Argentina
  • Blacktown Hospital ( Site 0201), Blacktown, New South Wales, Australia
  • Royal Brisbane and Women's Hospital ( Site 0206), Brisbane, Queensland, Australia
  • Epworth Freemasons ( Site 0207), Melbourne, Victoria, Australia
  • Sir Charles Gairdner Hospital ( Site 0203), Nedlands, Western Australia, Australia
  • Medizinische Universität Graz-Abteilung für Gynäkologie / Onkologie ( Site 0303), Graz, Styria, Austria
  • Medizinische Universitaet Innsbruck-Univ.-Klinik f. Gynäkologie und Geburtshilfe ( Site 0301), Innsbruck, Tyrol, Austria
  • Medizinische Universität Wien - Allg. Gynaekologie & Gyn. Onkologie ( Site 0302), Vienna, Austria
  • CHU Saint-Pierre ( Site 0405), Brussels, Bruxelles-Capitale, Region de, Belgium
  • AZ Maria Middelares ( Site 0402), Ghent, Oost-Vlaanderen, Belgium
  • UZ Leuven ( Site 0401), Leuven, Vlaams-Brabant, Belgium
  • Grand Hôpital de Charleroi ( Site 0403), Charleroi, Wallonne, Region, Belgium
  • CHU de Liege ( Site 0404), Liège, Wallonne, Region, Belgium
  • Hospital Araújo Jorge ( Site 0521), Goiânia, Goiás, Brazil
  • Liga Norte Riograndense Contra o Câncer ( Site 0523), Natal, Rio Grande do Norte, Brazil
  • Hospital São Lucas da PUCRS ( Site 0522), Porto Alegre, Rio Grande do Sul, Brazil
  • IBCC - Instituto Brasileiro de Controle do Câncer ( Site 0525), São Paulo, São Paulo, Brazil
  • Instituto Nacional de Câncer - INCA ( Site 0515), Rio de Janeiro, Brazil
  • BC Cancer Surrey ( Site 0621), Surrey, British Columbia, Canada
  • CancerCare Manitoba ( Site 0617), Winnipeg, Manitoba, Canada
  • NL Health Services ( Site 0602), St. John's, Newfoundland and Labrador, Canada
  • Royal Victoria Regional Health Centre ( Site 0615), Barrie, Ontario, Canada
  • London Health Sciences Centre ( Site 0611), London, Ontario, Canada
  • Sault Area Hospital ( Site 0616), Sault Ste. Marie, Ontario, Canada
  • Sunnybrook Research Institute ( Site 0610), Toronto, Ontario, Canada
  • Princess Margaret Cancer Center ( Site 0609), Toronto, Ontario, Canada
  • Windsor Regional Cancer Program ( Site 0614), Windsor, Ontario, Canada
  • CIUSSS de l'Est-de-l'Île-de-Montréal ( Site 0607), Montreal, Quebec, Canada
  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0605), Montreal, Quebec, Canada
  • Jewish General Hospital ( Site 0606), Montreal, Quebec, Canada
  • McGill University Health Centre ( Site 0604), Montreal, Quebec, Canada
  • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0608), Sherbrooke, Quebec, Canada
  • Centro de Estudios Clínicos SAGA ( Site 0708), Santiago, Region M. de Santiago, Chile
  • Fundación Arturo López Pérez ( Site 0702), Santiago, Region M. de Santiago, Chile
  • Pontificia Universidad Catolica de Chile ( Site 0705), Santiago, Region M. de Santiago, Chile
  • Bradfordhill ( Site 0703), Santiago, Region M. de Santiago, Chile
  • ONCOCENTRO APYS ( Site 0704), Viña del Mar, Valparaiso, Chile
  • Anhui Provincial Hospital ( Site 0830), Hefei, Anhui, China
  • Peking University Peoples Hospital ( Site 0845), Beijing, Beijing Municipality, China
  • Chongqing University Cancer Hospital ( Site 0838), Chongqing, Chongqing Municipality, China
  • Fujian Province Cancer Hospital ( Site 0802), Fuzhou, Fujian, China
  • The First Affiliated hospital of Xiamen University ( Site 0822), Xiamen, Fujian, China
  • Sun Yat-sen University Cancer Center ( Site 0846), Guangzhou, Guangdong, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 0801), Guangzhou, Guangdong, China
  • Zhujiang Hospital of Southern Medical University ( Site 0829), Guangzhou, Guangdong, China
  • Cancer Hospital of Shantou University Medical College ( Site 0827), Shantou, Guangdong, China
  • Affiliated Hospital of Guangdong Medical University ( Site 0823), Zhanjiang, Guangdong, China
  • Liuzhou People's Hospital ( Site 0831), Liuzhou, Guangxi, China
  • Guangxi Medical University Affiliated Tumor Hospital. ( Site 0825), Nanning, Guangxi, China
  • Harbin Medical University Cancer Hospital ( Site 0850), Harbin, Heilongjiang, China
  • Henan Cancer Hospital ( Site 0806), Zhengzhou, Henan, China
  • The Second Affiliated Hospital of Zhengzhou University ( Site 0833), Zhengzhou, Henan, China
  • Wuhan Union Hospital Cancer Center ( Site 0824), Wuhan, Hubei, China
  • Xiangya Hospital Central South University ( Site 0821), Changsha, Hunan, China
  • Hunan Cancer Hospital ( Site 0826), Changsha, Hunan, China
  • Nanjing First Hospital ( Site 0828), Nanjing, Jiangsu, China
  • Jiangxi Maternal and Child Health Hospital ( Site 0807), Nanchang, Jiangxi, China
  • The First Hospital Of Jilin University ( Site 0815), Changchun, Jilin, China
  • The First Affiliated Hospital of Xi'an Jiaotong University ( Site 0816), Xi'an, Shaanxi, China
  • Shandong Cancer Hospital ( Site 0803), Jinan, Shandong, China
  • LinYi Cancer Hospital ( Site 0820), Linyi, Shandong, China
  • Shanghai Tenth People's Hospital ( Site 0847), Shanghai, Shanghai Municipality, China
  • Obstetrics & Gynecology Hospital of Fudan University ( Site 0818), Shanghai, Shanghai Municipality, China
  • Shanxi Provincial Cancer Hospital ( Site 0843), Taiyuan, Shanxi, China
  • West China Second University Hospital, Sichuan University ( Site 0849), Chengdu, Sichuan, China
  • The Second People's Hospital of Yibin ( Site 0840), Yibin, Sichuan, China
  • Yunnan Province Cancer Hospital ( Site 0811), Kunming, Yunnan, China
  • The Affiliated Women's Hospital of Zhejiang University ( Site 0834), Hangzhou, Zhejiang, China
  • Taizhou Hospital of Zhejiang Province ( Site 0809), Linhai, Zhejiang, China
  • The First Affiliated Hospital of Wenzhou Medical University ( Site 0805), Wenzhou, Zhejiang, China
  • Promotora Médica las Américas S.A ( Site 0904), Medellín, Antioquia, Colombia
  • Fundacion Colombiana de Cancerología Clinica Vida ( Site 0905), Medellín, Antioquia, Colombia
  • FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0902), Bogotá, Bogota D.C., Colombia
  • Oncologos Del Occidente ( Site 0907), Pereira, Risaralda Department, Colombia
  • Fakultni nemocnice Ostrava ( Site 1104), Ostrava, Ostrava Mesto, Czechia
  • Nemocnice AGEL Novy Jicin a.s. ( Site 1102), Nový Jičín, Czechia
  • Vseobecna fakultni nemocnice v Praze-Gynekologicko-porodnicka klinika 1.LF a VFN ( Site 1101), Prague, Czechia
  • Fakultní nemocnice Motol a Homolka ( Site 1103), Prague, Czechia
  • Herlev and Gentofte Hospital ( Site 1202), Copenhagen, Capital Region, Denmark
  • Aarhus Universitetshospital, Skejby ( Site 1205), Aarhus, Central Jutland, Denmark
  • Aalborg Universitetshospital, Syd ( Site 1203), Aalborg, North Denmark, Denmark
  • Sjællands Universitetshospital Køge ( Site 1204), Koege, Region Sjælland, Denmark
  • Kuopion Yliopistollinen Sairaala ( Site 1304), Kuopio, Northern Savonia, Finland
  • Tampereen yliopistollinen sairaala ( Site 1303), Tampere, Pirkanmaa, Finland
  • Turku University Hospital-Department of Obstetrics and Gynecology ( Site 1302), Turku, Southwest Finland, Finland
  • Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 1301), Helsinki, Uusimaa, Finland
  • Institut Paoli Calmettes ( Site 1410), Marseille, Bouches-du-Rhone, France
  • Centre Francois Baclesse ( Site 1412), Caen, Calvados, France
  • Hôpital Privé Des Côtes d'Armor ( Site 1404), Plérin, Cotes-d Armor, France
  • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 1405), Bordeaux, Gironde, France
  • LBM ONCOPOLE CLAUDIUS REGAUD ( Site 1407), Toulouse, Haute-Garonne, France
  • Institut Curie - site Saint-Cloud ( Site 1408), Saint-Cloud, Hauts-de-Seine, France
  • Institut De Cancerologie De L Ouest ( Site 1403), Saint-Herblain, Loire-Atlantique, France
  • CENTRE LEON BERARD ( Site 1401), Lyon, Rhone, France
  • Groupe Hospitalier Diaconesses Croix Saint Simon ( Site 1409), Paris, France
  • Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 1411), Paris, France
  • Klinikum Kassel GmbH ( Site 1510), Kassel, Hesse, Germany
  • Universitaetsklinikum Aachen ( Site 1507), Aachen, North Rhine-Westphalia, Germany
  • Universitaetsklinikum Bonn ( Site 1504), Bonn, North Rhine-Westphalia, Germany
  • Klinikum Lippe Detmold ( Site 1522), Detmold, North Rhine-Westphalia, Germany
  • Klinikum Mutterhaus der Borromäerinnen ( Site 1506), Trier, Rhineland-Palatinate, Germany
  • CaritasKlinikum Saarbruecken St. Theresia ( Site 1508), Saarbrücken, Saarland, Germany
  • Universitaetsklinikum Leipzig ( Site 1505), Leipzig, Saxony, Germany
  • Staedtisches Klinikum Dessau ( Site 1521), Dessau, Saxony-Anhalt, Germany
  • Universitaetsklinikum Jena ( Site 1503), Jena, Thuringia, Germany
  • Charité Campus Virchow-Klinikum ( Site 1501), Berlin, Germany
  • Asklepios Kliniken Hamburg ( Site 1509), Hamburg, Germany
  • Alexandra General Hospital of Athens ( Site 1604), Athens, Attica, Greece
  • Aretaieio Hospital ( Site 1602), Athens, Attica, Greece
  • ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1603), Chaïdári, Attica, Greece
  • Iaso General Clinic ( Site 1605), Marousi, Attica, Greece
  • Agios Loukas Clinic-DEPARTMENT OF ONCOLOGY ( Site 1601), Thessaloniki, Central Macedonia, Greece
  • Semmelweis Egyetem Szuleszeti es Nogyogyaszati Klinika ( Site 1703), Budapest, Hungary
  • Országos Onkológiai Intézet-Ngyógyászat ( Site 1702), Budapest, Hungary
  • Debreceni Egyetem Klinikai Kozpont-Szülészeti és Nőgyógyászati Klinika ( Site 1701), Debrecen, Hungary
  • St. Vincent's University Hospital ( Site 1902), Dublin, Dublin, Ireland
  • Cork University Hospital ( Site 1903), Cork, Ireland
  • Mater Misericordiae University Hospital ( Site 1904), Dublin, Ireland
  • St. James's Hospital ( Site 1901), Dublin, Ireland
  • Rambam Health Care Campus ( Site 2025), Haifa, Israel
  • Carmel Hospital ( Site 2023), Haifa, Israel
  • Shaare Zedek Medical Center ( Site 2020), Jerusalem, Israel
  • Meir Medical Center. ( Site 2021), Kfar Saba, Israel
  • Sourasky Medical Center ( Site 2022), Tel Aviv, Israel
  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 2107), Meldola, Forli-Cesena, Italy
  • Ospedale Humanitas San Pio X ( Site 2106), Milan, Lombardy, Italy
  • Ospedale Cannizzaro ( Site 2103), Catania, Italy
  • Azienda Ospedaliera Universitaria Careggi ( Site 2109), Florence, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 2114), Milan, Italy
  • Istituto Europeo di Oncologia ( Site 2110), Milan, Italy
  • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 2104), Naples, Italy
  • Azienda Ospedaliero Universitaria Pisana Ospedale S. Chiara ( Site 2108), Pisa, Italy
  • Istituto Nazionale Tumori Regina Elena ( Site 2102), Roma, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli ( Site 2105), Roma, Italy
  • Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino ( Site 2111), Torino, Italy
  • Ospedale Mauriziano ( Site 2101), Torino, Italy
  • Ospedale Santa Maria di Ca' Foncello ( Site 2112), Treviso, Italy
  • Aichi Cancer Center ( Site 2217), Nagoya, Aichi-ken, Japan
  • National Hospital Organization Shikoku Cancer Center ( Site 2206), Matsuyama, Ehime, Japan
  • Ehime University Hospital ( Site 2213), Tōon, Ehime, Japan
  • Kurume University Hospital ( Site 2204), Kurume, Fukuoka, Japan
  • Gunma Prefectural Cancer Center ( Site 2202), Ōta, Gunma, Japan
  • National Hospital Organization Hokkaido Cancer Center ( Site 2212), Sapporo, Hokkaido, Japan
  • Hyogo Cancer Center ( Site 2216), Akashi, Hyōgo, Japan
  • Iwate Medical University Hospital ( Site 2207), Shiwa-gun, Iwate, Japan
  • Saitama Medical University International Medical Center ( Site 2201), Hidaka, Saitama, Japan
  • Shizuoka Cancer Center ( Site 2205), Sunto-gun, Shizuoka, Japan
  • National Cancer Center Hospital ( Site 2211), Chūō, Tokyo, Japan
  • Cancer Institute Hospital of JFCR ( Site 2208), Koto, Tokyo, Japan
  • Keio University Hospital ( Site 2209), Shinjuku, Tokyo, Japan
  • National Hospital Organization Kyushu Cancer Center ( Site 2203), Fukuoka, Japan
  • Fukushima Medical University Hospital ( Site 2218), Fukushima, Japan
  • Niigata Cancer Center Hospital ( Site 2210), Niigata, Japan
  • Okayama University Hospital ( Site 2215), Okayama, Japan
  • Yamagata University Hospital ( Site 2219), Yamagata, Japan
  • CIO - Centro de Inmuno-Oncología de Occidente ( Site 2402), Guadalajara, Jalisco, Mexico
  • Laboratorio de Patología Clínica del Hospital Universitario "Dr. José Eleuterio González" ( Site 2401), Monterrey, Nuevo León, Mexico
  • Centro de Investigacion Clinica de Oaxaca ( Site 2404), Oaxaca City, Oaxaca, Mexico
  • Centro de Investigación Oncológica Galerías SC ( Site 2405), Aguascalientes, Mexico
  • Sitio Clínico UIS Chihuahua (Operadora Unidad de Investigación en Salud de Chihuahua SA de CV) ( Site 2406), Chihuahua City, Mexico
  • Maastricht UMC+ ( Site 2501), Maastricht, Limburg, Netherlands
  • Universitair Medisch Centrum Utrecht ( Site 2503), Utrecht, Netherlands
  • Stavanger Universitetssykehus ( Site 2703), Norway, Rogaland, Norway
  • Universitetssykehuset Nord-Norge HF ( Site 2702), Tromsø, Troms, Norway
  • Oslo universitetssykehus, Radiumhospitalet ( Site 2701), Oslo, Norway
  • Clínica San Felipe ( Site 2804), Jesus Maria, Lima region, Peru
  • IPOR Instituto Peruano de Oncología & Radioterapia ( Site 2803), San Isidro, Lima region, Peru
  • INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 2805), Lima, Peru
  • Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 3011), Poznan, Greater Poland Voivodeship, Poland
  • Wielkopolskie Centrum Onkologii im. Marii Skłodowskiej-Curie ( Site 3003), Poznan, Greater Poland Voivodeship, Poland
  • Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 3004), Siedlce, Masovian Voivodeship, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 3002), Warsaw, Masovian Voivodeship, Poland
  • Bialostockie Centrum Onkologii ( Site 3007), Bialystok, Podlaskie Voivodeship, Poland
  • Uniwersyteckie Centrum Kliniczne-Klinika Ginekologii, Ginekologii Onkologicznej i Endokrynologii Gi ( Site 3001), Gdansk, Pomeranian Voivodeship, Poland
  • Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 3006), Gliwice, Silesian Voivodeship, Poland
  • Swietokrzyskie Centrum Onkologii. ( Site 3008), Kielce, Świętokrzyskie Voivodeship, Poland
  • Puerto Rico Cancer Specialists Clinical Trials ( Site 4201), San Juan, Puerto Rico
  • National University Hospital ( Site 3202), Singapore, Central Singapore, Singapore
  • National Cancer Centre Singapore ( Site 3201), Singapore, Central Singapore, Singapore
  • National Cancer Center ( Site 3106), Gyeonggi-do, Kyonggi-do, South Korea
  • Keimyung University Dongsan Hospital ( Site 3105), Daegu, Taegu-Kwangyokshi, South Korea
  • Seoul National University Hospital ( Site 3102), Seoul, South Korea
  • Severance Hospital, Yonsei University Health System ( Site 3101), Seoul, South Korea
  • Asan Medical Center ( Site 3103), Seoul, South Korea
  • Samsung Medical Center ( Site 3104), Seoul, South Korea
  • Institut Català d'Oncologia - L'Hospitalet ( Site 3408), L'Hospitalet de Llobregat, Barcelona, Spain
  • Institut Català d'Oncologia (ICO) - Girona ( Site 3407), Girona, Gerona, Spain
  • Hospital Universitari Vall d''Hebron ( Site 3401), Barcelona, Spain
  • Hospital Universitario Reina Sofia ( Site 3402), Córdoba, Spain
  • Hospital Universitario Ramon y Cajal ( Site 3403), Madrid, Spain
  • Hospital Universitario 12 de Octubre ( Site 3404), Madrid, Spain
  • Hospital Universitario La Paz ( Site 3406), Madrid, Spain
  • Fundación Instituto Valenciano de Oncología ( Site 3405), Valencia, Spain
  • Skånes Universitetssjukhus Lund ( Site 3502), Lund, Skåne County, Sweden
  • Akademiska Sjukhuset ( Site 3501), Uppsala, Uppsala County, Sweden
  • Taichung Veterans General Hospital ( Site 3703), Taichung, Taiwan
  • National Cheng Kung University Hospital ( Site 3702), Tainan, Taiwan
  • National Taiwan University Hospital ( Site 3701), Taipei, Taiwan
  • Mackay Memorial Hospital ( Site 3704), Taipei, Taiwan
  • Linkou Chang Gung Memorial Hospital ( Site 3705), Taoyuan, Taiwan
  • Ramathibodi Hospital. ( Site 3802), Bangkok, Bangkok, Thailand
  • Faculty of Medicine Siriraj Hospital ( Site 3801), Bangkok, Bangkok, Thailand
  • Maharaj Nakorn Chiang Mai Hospital ( Site 3804), Chiang Mai, Thailand
  • Faculty of Medicine - Khon Kaen University ( Site 3803), Khon Kaen, Thailand
  • University Hospitals Sussex NHS Foundation Trust ( Site 4011), East Sussex, Brighton And Hove, United Kingdom
  • Addenbrookes Hospital ( Site 4002), Cambridge, Cambridgeshire, United Kingdom
  • The Beatson West of Scotland Cancer Centre ( Site 4004), Glasgow, Glasgow City, United Kingdom
  • University College London Hospital ( Site 4001), London, London, City of, United Kingdom
  • ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 4006), London, London, City of, United Kingdom
  • Hammersmith Hospital ( Site 4010), London, London, City of, United Kingdom
  • Western General Hospital ( Site 4012), Edinburgh, Midlothian, United Kingdom
  • Royal Marsden Hospital (Sutton) ( Site 4005), London, Surrey, United Kingdom
  • Leicester Royal Infirmary ( Site 4008), Leicester, United Kingdom
  • Maidstone Hospital ( Site 4007), Maidstone, United Kingdom
  • The Christie NHS Foundation Trust ( Site 4003), Manchester, United Kingdom
Key criteria · Original registry text

Key inclusion criteria include but are not limited to: * Has a histologically confirmed diagnosis of primary advanced or recurrent endometrial carcinoma that has been confirmed as proficient mismatch repair (pMMR) * Has radiographically evaluable disease, with measurable Stage III or either measurable or non-measurable Stage IV or recurrent disease per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1), as assessed by the investigator * Has received no prior systemic therapy for endometrial carcinoma except the following conditions as pre-specified by the protocol: 1 prior line of systemic platinum-based adjuvant and/or neoadjuvant chemotherapy in the setting of curative-intent, prior radiation with or without radiosensitizing chemotherapy if \>2 weeks before the start of induction treatment, or prior hormonal therapy for treatment of endometrial carcinoma that was discontinued ≥1 week before the start of induction treatment Key exclusion criteria include but are not limited to: * Has carcinosarcoma, neuroendocrine tumors or endometrial sarcoma, including stromal sarcoma, leiomyosarcoma, adenosarcoma, or other types of sarcomas * Has endometrial carcinoma of any histology that is mismatch repair deficient (dMMR) * Is a candidate for debulking surgery resulting in complete removal of all tumor and no evidence of radiological disease following surgery, or curative-intent radiotherapy at the time of enrollment * Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease * Human Immunodeficiency Virus-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Received prior therapy in any setting with any of the following: anti-programmed cell death 1 protein, anti-programmed cell death ligand 1, anti-programmed cell death ligand 2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor; trophoblast cell surface antigen 2-targeted antibody drug conjugate; or topoisomerase I inhibitor-containing antibody drug conjugate

NCT07169630Recruiting

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

Alzheimer s Disease · Mild Cognitive Impairment · Healthy

Why this research matters

Original registry summary

Background: About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias. The number of people with these disorders will likely increase as the population ages and life span increases. Inflammation is thought to play a role in AD and MCI. Researchers want to know if an enzyme called PDE4B increases inflammation in people with AD or MCI. Objective: To test whether medical imaging using a new radiotracer (\[18F\]PF-06445974) can measure PDE4B in the brains of people with AD or MCI. Eligibility: People aged 50 years and older with AD or MCI. Healthy volunteers are also needed. Design: Participants will have up to 5 clinic visits with 3 imaging scans of the brain. They will have be screened. They will have a physical exam with blood tests. This will include tests of their heart and nerve function, including memory. Participants will have 2 positron emission tomography (PET) scans. One will use a standard radiotracer. The other will use the study radiotracer. They will receive each tracer through a tube attached to a needle inserted into a vein. During the scan with the study tracer, participants will have a second tube inserted into a vein in the wrist; this tube will be used to draw blood during the scan. Participants will lie on a bed that slides into a doughnut-shaped machine. These visits will take about 6 hours each. Participants will have 1 magnetic resonance imaging (MRI) scan. They will lie on a bed that slides into a cylinder. This visit will take up to 2 hours....

Who may participate

Age
50 Years – 100 Years
Sex
All
Healthy volunteers
Yes
Study type
Interventional

Location

  • National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Key criteria · Original registry text

* INCLUSION CRITERIA: Participants will be referred by a physician with the suspected diagnosis of AD or MCI. However, the PI of this protocol will provide the final diagnosis. For this reason, this protocol will have just one consent form for participants suspected of having either AD or MCI. AD and MCI Study Groups: Participants must meet all the following criteria: * Aged 50 or older. * Be able (or have their Legally Authorized Representative (LAR) be able) to understand the study and be willing to sign a written informed consent document. * Have been diagnosed by a neurologist or psychiatrist with MCI or AD. * Be in good general health as evidenced by medical history and physical examination. * Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists. * Agree to adhere to the lifestyle considerations. Healthy Volunteers: Participants must meet all the following criteria: * Aged 50 or older. * Able to provide informed consent. * Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment. * Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists. * Agree to adhere to the lifestyle considerations. EXCLUSION CRITERIA: Both the study groups will be excluded if they meet any of the following criteria: * Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). * Participants should not have taken non-steroidal anti-inflammatory drugs (NSAIDs) for two weeks prior to the PET scan. Aspirin, corticosteroids (with the exception of skin products), or immunosuppressants (e.g., methotrexate) must not have been taken in the prior month. * Have other major neurological or medical diseases that may cause cognitive dysfunction, such as structural brain diseases, metabolic diseases, paraneoplastic syndromes, infectious diseases, or other significant neurological abnormalities. * Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy). * Are unable to travel to the NIH. * Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits. * Have an inability to lie flat and/or lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the volunteer and/or caregiver during the screening visit. * Participants must not have substance use disorder or alcohol use disorder. * Participants should not be under treatment or previously treated with an amyloid antibody such as lecanemab. * Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye). * Pregnancy or breast feeding. * HIV infection. * Non-English speaking participants. Exclusion of Children: Inclusion of children is not appropriate, because this protocol has more than minimal risk from radiation exposure without the possibility of direct benefit. Exclusion of Pregnant or Breastfeeding Women: Pregnant women will be excluded because this protocol involves exposure to ionizing radiation. Lactating women will be excluded because radioisotopes may be excreted in milk. We will not require contraception for this protocol to allow participants autonomy in medical decision-making. However, while we will not require contraception for woman of childbearing potential, we will perform a pregnancy test at screening and prior to all procedures to ensure participants are not pregnant Exclusion of Participants who are HIV Positive: Persons with HIV infection are excluded because HIV infection itself may change cAMP signaling. Exclusion of Non-English-Speaking Participants: Non-English-speaking participants will be excluded from participation in this study because neuropsychological testing is required by this protocol. This testing, which is critical for interpreting study results, has not been validated in other languages or when using a translator.

NCT07173933Recruiting

Evaluation of the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD)

Wilson Disease

Why this research matters

Original registry summary

The goal of this clinical trial is to learn if GC310 (AAV5-ATP7B) gene therapy can treat Wilson's Disease (WD) in patients over the age of 18 years old. The main questions it aims to answer are: Is GC310 safe and tolerable to WD patients? What is the recommended phase II dose (RP2D)? What is the change from baseline in 24-hour urinary copper concentration after 52 weeks of administration? Participants will be administrated GC310 intravenously and be followed up for 52 weeks to observe drug safety, tolerability and efficacy .

Who may participate

Age
18 Years – Not specified
Sex
All
Healthy volunteers
No
Study type
Interventional

Location

  • Peking Union Medical College, Beijing, China
Key criteria · Original registry text

Inclusion Criteria: * Aged ≥ 18 years, sex unrestricted; * Definitive diagnosis of Wilson disease (WD) based on: (i) or (ii) + (iii) and (iv), or (i) or (ii) + (v); (i) Neurological and/or psychiatric symptoms; (ii) Unexplained liver injury; (iii) Reduced serum ceruloplasmin and/or elevated 24-hour urinary copper; (iv) Positive corneal Kayser-Fleischer (K-F) ring; (v) Biallelic pathogenic ATP7B variants confirmed by segregation analysis and variant pathogenicity assessment; * Serum ceruloplasmin concentration \< ½ × lower limit of normal (LLN); * Willing and able to comply with all study procedures, and has provided written informed consent. Exclusion Criteria: Subjects meeting ANY of the following criteria will be excluded: 1. Screening serum anti-AAV5 neutralizing antibody titre \> 1:100. 2. Clinically significant laboratory abnormality at screening or baseline: 1. ALT or AST ≥ 5 × ULN, direct bilirubin \> 1 × ULN, or albumin \< 1 × LLN; 2. Blood ammonia \> 1 × ULN. 3. Renal impairment (any degree). 4. Current hepatic decompensation or history of hepatic decompensation. 5. Liver stiffness measurement (LSM) ≥ 15 kPa by transient elastography at screening. 6. History of acute liver failure from any cause. 7. Evidence of advanced liver disease defined by either: 1. MELD score ≥ 12, or 2. Child-Pugh score ≥ 7. 8. Severe neuro-psychiatric manifestations that, in the investigator's opinion, could compromise subject safety or interfere with study participation. 9. Positive for HIV antibody, hepatitis C antibody, Treponema pallidum antibody, or hepatitis B surface antigen. 10. Contraindications to glucocorticoid therapy judged by the investigator (e.g., uncontrolled hypertension, systemic fungal infection, glaucoma, osteoporosis, active tuberculosis). 11. Concurrent conditions that may interfere with study conduct or assessment, including significant gastrointestinal, cardiovascular, cerebrovascular, renal, endocrine, haematological, immunological, neurological or psychiatric disorders other than Wilson disease. 12. Pregnant or lactating women. 13. Women of child-bearing potential or fertile men who plan to conceive within 1 year after dosing or are unwilling to use highly effective contraception. 14. Body-mass index ≥ 24 kg/m². 15. History of severe hypersensitivity to foods or drugs, including recombinant proteins. 16. Vaccination within 2 weeks prior to planned dosing. 17. Prior exposure to any gene-therapy product. 18. Participation in any other clinical trial (WD-related or not) within 3 months before screening. 19. Any other condition or circumstance that, in the opinion of the investigator, renders the subject unsuitable for the study (e.g., poor compliance).

NCT07932080Recruiting

Evaluation of the Predictive Value of Microemboli Detected by Robotic Transcranial Doppler (TCD) for the Occurrence of an Acute Ischemic Stroke (AIS) or Left Ventricular Thrombus (LVT) in ST Elevation Myocardial Infarction (STEMI) Patients With Left Ventricular Dysfunction (LVD).

STEMI · Left Ventricular Thrombus · Acute Ischemic Stroke

Why this research matters

Original registry summary

The goal of this study is to define a correlation between the number of microembolic signals (MES) detected by the transcranial doppler and the risk of occurrence of an Acute Ischemic Stroke (AIS) at 2 years or a Left Ventricular Thrombus (LVT) at 6 weeks.

Who may participate

Age
18 Years – Not specified
Sex
All
Healthy volunteers
No
Study type
Interventional

Location

  • CHC MontLégia, Liège, Liège, Belgium
Key criteria · Original registry text

Inclusion Criteria: * Patient aged 18 or over * Patient with proven post-STEMI LVD within 72 hours of hospitalization for acute STEMI * Ejection fraction less than 35% * Express consent to participate in the study * Member or beneficiary of a social security scheme Exclusion Criteria: * Patient with known carotid stenosis greater than 50%. * Patient with a history of AIS * Patient with AF * Patient with mechanical valve * Patient benefiting from a legal protection measure * Pregnant or breast-feeding women * History of cardiorespiratory arrest * Life expectancy of \<6 months Secondary exclusion criteria * Withdrawal of consent to participate in the study

NCT06463587Recruiting

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Generalized Myasthenia Gravis

Why this research matters

Original registry summary

The purpose of this clinical study is to determine the efficacy and safety of a new oral cladribine formulation in participants with Generalized Myasthenia Gravis (gMG) in comparison to placebo. It will also investigate the sustained efficacy, the need for retreatment, and the long-term safety of oral cladribine in gMG. An additional component is included to characterize the Pharmacokinetics (PK) of the new cladribine formulation in gMG participants. This study is divided into 3 periods: the double-blind placebo control (DBPC) pivotal period, and 2 extensions, the blinded extension (BE) and the retreatment (RT) period. Furthermore, in trial interviews will be conducted as a sub-study to MyClad with a sub-set of participants to gain an in depth understanding of the participant cladribine treatment and study experience.

Who may participate

Age
18 Years – Not specified
Sex
All
Healthy volunteers
No
Study type
Interventional

Location

  • Arizona Neuroscience Research, LLC, Phoenix, Arizona, United States
  • Advanced Neurosciences Research LLC, Longmont, Colorado, United States
  • University of Connecticut Health Center - Department of Medicine, Farmington, Connecticut, United States
All listed locations
  • The George Washington University Medical Faculty Associates Foggy Bottom South Pavilion, Washington D.C., District of Columbia, United States
  • Neurology of Central Florida Research Center, LLC, Altamonte Springs, Florida, United States
  • SFM Clinical Research, LLC, Boca Raton, Florida, United States
  • University of Florida Health Science Center - 300120311, Jacksonville, Florida, United States
  • Neurology Associates, P. A., Maitland, Florida, United States
  • University of South Florida - PARENT - PARENT, Tampa, Florida, United States
  • University of Kansas Medical Center Research Institute, Inc. - 3901 Rainbow (MAIN), Kansas City, Kansas, United States
  • UNC Hospitals - PARENT, Chapel Hill, North Carolina, United States
  • Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States
  • Miami Valley Hospital South, Centerville, Ohio, United States
  • University of Cincinnati, Cincinnati, Ohio, United States
  • Clinical Trials of South Carolina - Charleston, Charleston, South Carolina, United States
  • Erlanger Health, Inc. - 1123255, Chattanooga, Tennessee, United States
  • Baylor Scott & White Research Institute - Baylor Scott & White Research Institute, Dallas, Texas, United States
  • ANESC Research, El Paso, Texas, United States
  • DHR Health Institute for Research and Development, McAllen, Texas, United States
  • Baylor Scott & White Neurology - McKinney, McKinney, Texas, United States
  • The University of Vermont Medical Center, Burlington, Vermont, United States
  • Integrated Neurology Services - Dr. Simon Fishman's Office, Falls Church, Virginia, United States
  • BCN Research, Greenfield, Wisconsin, United States
  • Expertia S.A- Mautalen Salud e Investigación, Ciudad Autonoma Buenos Aires, Argentina
  • Instituto de Investigaciones Neurologicas Raul Carrea, FLENI - de Investigaciones Clinicas del área de Cardiología y enfermedades metabólicas asociadas, Ciudad Autonoma Buenos Aires, Argentina
  • Instituto de Investigaciones Metabolicas (IDIM), Ciudad Autonoma Buenos Aires, Argentina
  • Hospital Cordoba, Córdoba, Argentina
  • Fundacion Rosarina de Neurorehabilitacion, Rosario, Argentina
  • INECO Neurociencias Oroño, Rosario, Argentina
  • CER San Juan Centro Polivalente de Asistencia e Inv. Clinica, San Juan, Argentina
  • Centro de Investigaciones Medicas Tucuman, San Miguel de Tucumán, Argentina
  • Brain and Mind Research Institute, Camperdown, New South Wales, Australia
  • Sunshine Coast University Hospital, Birtinya, Queensland, Australia
  • Princess Alexandra Hospital - PARENT, South Brisbane, Queensland, Australia
  • John Hunter Hospital - PARENT, City of Burnside, South Australia, Australia
  • Box Hill Hospital - PARENT, Box Hill, Victoria, Australia
  • Gold Coast University Hospital - PARENT, Southport, Australia
  • UZ Leuven, Leuven, Belgium
  • C. H. R. de la Citadelle - Account 1, Liège, Belgium
  • Medical Center Hera - branch Montana, Montana, Bulgaria
  • UMHAT 'Dr. Georgi Stranski', EAD, Pleven, Bulgaria
  • UMHAT "Sv. Georgi", EAD, Plovdiv, Bulgaria
  • MHATNP "Sv.Naum", EAD - Third Neurology Clinic, Sofia, Bulgaria
  • UMHATEM 'N.I. Pirogov', EAD, Sofia, Bulgaria
  • Burnaby Hospital - Fraser Health Multiple Sclerosis Clinic, Burnaby, British Columbia, Canada
  • The First Affiliated Hospital of Bengbu Medical College, Anhui Sheng, Anhui, China
  • Xuanwu Hospital Capital Medical University, Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
  • The First Affiliated Hospital of Guangzhou University of Chinese Medicine - 300164595, Guangzhou, Guangdong, China
  • Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
  • Shijiazhuang People's Hospital, Shijiazhuang, Hebei, China
  • Henan Provincial People's Hospital, Zhengzhou, Henan, China
  • Xiangya Hospital, Central South University, Changsha, Hu'nan, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China
  • The First Hospital of Jilin University - The First Hospital of Jilin University, Changchun, Jilin, China
  • China-Japan Union Hospital of Jilin University - 300173736, Changchun, Jilin, China
  • Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
  • Huashan Hospital, Fudan University - Neurology, Shanghai, Shanghai Municipality, China
  • Xi 'an International Medical Center, Xi’an, Shanxi, China
  • West China Hospital, Sichuan University, Chengdu, Sichuan, China
  • CHU Nice - Hôpital Pasteur - Cardiology, Nice, Alpes Maritimes, France
  • CHU Strasbourg - Hopital Hautepierre - Service Anesthesie-Reanimation&Medecine Peri-Opera, Strasbourg, Bas Rhin, France
  • CHU de Grenoble - Hôpital Albert Michallon - Centre de Références des Maladies Neuromusculaires, La Tronche, Isere, France
  • Fondation Ophtalmologique Adolphe de Rothschild - Service de neurologie, Paris, Paris, France
  • CHU Clermont Ferrand - Hopital Gabriel Montpied - service de neurologie B, Clermont-Ferrand, Puy De Dome, France
  • Hopital Neurologique Pierre Wertheimer - Pathologies neuro-musculaires. Electromyographie, Bron, Rhone, France
  • Hôpital Henri Mondor - Service de Neurologie, Créteil, Val De Marne, France
  • Groupe Hospitalier Pitie-Salpetriere - Centre Référent Maladies Rares SLA - Neurologie, Paris, France
  • Ltd. Pineo Medical Ecosystem, Tbilisi, Georgia
  • New Hospitals LLC, Tbilisi, Georgia
  • Aversi Clinic Ltd, Tbilisi, Georgia
  • Universitaetsklinikum Ulm - Klinik fuer Neurologie, Ulm, Baden-Wurttemberg, Germany
  • Universitaetsmedizin Goettingen - Abteilung fuer Nephrologie und Rheumatologie, Göttingen, Lower Saxony, Germany
  • Medizinische Hochschule Hannover - Klinik fur Neurologie mit Klinischer Neurophysiol, Hanover, Lower Saxony, Germany
  • St. Joseph Hospital - St. Joseph Hospital Haan, Bochum, North Rhine-Westphalia, Germany
  • Universitaetsklinikum Duesseldorf AoeR - Klinik fuer Neurologie, Düsseldorf, North Rhine-Westphalia, Germany
  • Universitaetsklinikum Carl Gustav Carus TU Dresden - Medizinische Klinik I, Dresden, Saxony, Germany
  • Universitaetsklinikum Leipzig AoeR - Klinik und Poliklinik fuer Neurologie, Leipzig, Saxony, Germany
  • Universitaetsklinikum Schleswig-Holstein - Campus Luebeck - Neurologie, Lübeck, Schleswig-Holstein, Germany
  • Charité Universitaetsmedizin Berlin - Campus Charité Mitte - Klinik fuer Neurologie, Berlin, Germany
  • University General Hospital of Larissa - Rheumatology Clinic, Larissa, Greece
  • University Hospital of Patra, Pátrai, Greece
  • AHEPA General Hospital of Thessaloniki, Thessaloniki, Greece
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont - Neurologiai Klinika, Szeged, Hungary
  • Nizam's Institute of Medical Sciences, Hyderabad, Andhra Pradesh, India
  • Yashoda Super Speciality Hospital - 300158817, Hyderabad, Andhra Pradesh, India
  • Bangalore Medical College and Victoria Hospital - 300148268, Bangalore, Karnataka, India
  • St John's Medical College Hospital, Bangalore, Karnataka, India
  • Mallikatta Neurocentre, Mangalore, Karnataka, India
  • Renai Medicity Multi Super Specialty Hospital, Kochi, Kerala, India
  • ELIOS Hospital, Nagpur, Maharashtra, India
  • Chopda Medicare & Research Centre - 300188248, Nashik, Maharashtra, India
  • Deenanath Mangeshkar Hospital and Research Centre - Department of Neurology, Pune, Maharashtra, India
  • All India Institute of Medical Sciences, New Delhi, India
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII - PARENT, Bergamo, Italy
  • IRCCS Istituto delle Scienze Neurologiche di Bologna - Unità Operativa Complessa Clinica Neurologica, Bologna, Italy
  • IRCCS Ospedale Policlinico San Martino - Neuroradiologia, Genova, Italy
  • Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
  • Fondazione Istituto Neurologico Casimiro Mondino - Neurology, Pavia, Italy
  • Azienda Ospedaliera Universitaria Policlinico Tor Vergata - U.O.C. Neurologia, Rome, Italy
  • Policlinico Universitario Agostino Gemelli - UOC Neurologia, Rome, Italy
  • Ospedale ca' Foncello - Neurology, Treviso, Italy
  • Chiba University Hospital - Dept of Neurology, Chiba, Chiba, Japan
  • IUHW Narita Hospital - Dept of Neurology, Narita-shi, Chiba, Japan
  • Fukuoka University Hospital - Dept of Neurology/Health Care, Fukuoka, Fukuoka, Japan
  • Southern Tohoku Medical Clinic - Dept of Neurology, Koriyama-shi, Fukushima, Japan
  • Hakodate Municipal Hospital - Dept of Neurology, Hakodate-shi, Hokkaido, Japan
  • General Hanamaki Hospital - Dept of Neurology, Hanamaki-shi, Iwate, Japan
  • Kagawa University Hospital - Dept of Neurology, Kita-gun, Kagawa-ken, Japan
  • Nagasaki University Hospital - Dept of Neurology, Nagasaki, Nagasaki, Japan
  • Saitama Medical University Hospital - Dept of Neurology/Stroke Care Unit, Iruma-gun, Saitama, Japan
  • Toho University Ohashi Medical Center - Dept of Neurology, Meguro-ku, Tokyo-To, Japan
  • Tokyo Medical University Hospital - Dept of Neurology, Shinjuku-ku, Tokyo-To, Japan
  • Osaka University Hospital - Dept of Neurology/Stroke Care Unit, Suita-shi, Japan
  • Uniwersyteckie Centrum Kliniczne - Dept of Neurology, Gdansk, Poland
  • SP ZOZ Szpital Uniwersytecki w Krakowie - Zespó, Krakow, Poland
  • Krakowska Akademia Neurologii Sp z o.o. Centrum Neurologii Klinicznej, Krakow, Poland
  • MTZ Clinical Research Powered By Pratia, Warsaw, Poland
  • Wielospecjalistyczne Centrum Medyczne Ibismed - Dept of Neurology, Zabrze, Poland
  • Institutul Clinic Fundeni - parent, Bucharest, Romania
  • S.C Neurocity S.R.L, Bucharest, Romania
  • Brainaxy Clinic S.R.L., Constanța, Romania
  • Spitalul Clinic Judetean de Urgenta Targu Mures - Sectia Clinica Neurologie I, Târgu Mureş, Romania
  • University Clinical Center of Serbia - Clinic of Neurology, Belgrade, Serbia
  • University Clinical Center Kragujevac - Department of Neurology, Kragujevac, Serbia
  • University Clinical Center Nis - Parent, Niš, Serbia
  • Clinical Center of Vojvodina - Department of Neurology, Novi Sad, Serbia
  • Wits Clinical Research - Chris Hani Baragwanath Hospital, Johannesburg, Gauteng, South Africa
  • Kyungpook National University Chilgok Hospital, Daegu, South Korea
  • Chonnam National University Hospital, Gwangju, South Korea
  • Severance Hospital, Yonsei University Health System - Division of Infectious Diseases, Seoul, South Korea
  • Samsung Medical Center, Seoul, South Korea
  • Korea University Anam Hospital, Seoul, South Korea
  • Asan Medical Center, Seoul, South Korea
  • Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, South Korea
  • Keimyung University Dongsan Hospital, Seoul, South Korea
  • Hospital Universitari Germans Trias i Pujol - Servicio de Neurologia, Badalona, Barcelona, Spain
  • Hospital Universitario Reina Sofia - Neurology Dept, Córdoba, Córdoba, Spain
  • Hospital Universitario Central de Asturias - Servicio de Neurologia, Oviedo, Principality of Asturias, Spain
  • Hospital Universitari Vall d'Hebron - Neurology Dept, Barcelona, Spain
  • Hospital Universitari i Politecnic La Fe - Pediatry Department, Valencia, Spain
  • Sahlgrenska Sjukhuset, Göteborg, Sweden
  • Centralsjukhuset Karlstad, Karlstad, Sweden
  • Danderyd Sjukhus - 300147691, Stockholm, Sweden
  • Inselspital - Universitaetsspital Bern - Neuropsychologische Rehabilitation, Neurologie, Bern, Switzerland
  • Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan
  • China Medical University Hospital, Taichung, Taiwan
  • Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
  • Taipei Veterans General Hospital, Taipei, Taiwan
  • Hacettepe University Medical Faculty - Neurology Department, Ankara, Turkey (Türkiye)
  • Ondokuz Mayis Univ. Med. Fac. - Neurology, Atakum/SAMSUN, Turkey (Türkiye)
  • Istanbul University Istanbul Medical Faculty - Neurology, Istanbul, Turkey (Türkiye)
  • Dokuz Eylul University Faculty of Medicine - Neurology Department, Izmir, Turkey (Türkiye)
  • Kocaeli University Medical Faculty - Neurology Department, Kocaeli, Turkey (Türkiye)
  • Mersin University Medical Faculty - Neurology Department, Mersin, Turkey (Türkiye)
  • Karadeniz Tecnical Uni. Med. Fac. - Neurology Departmen, Trabzon, Turkey (Türkiye)
  • Queen Square Centre for Neuromuscular Diseases, London, Greater London, United Kingdom
  • Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom
  • Royal Hallamshire Hospital - Dept of Neurology, Sheffield, South Yorkshire, United Kingdom
Key criteria · Original registry text

Inclusion Criteria: * Adults of ≥ 18 years of age at the time of signing the informed consent. * Diagnosis of Myasthenia Gravis with generalized muscle weakness, meeting clinical criteria for Myasthenia Gravis Foundation of America Class II to IVa classification. * In participants positive for Acetylcholine receptor antibody (anti-AChR) or muscle-specific kinase antibody(anti-MuSK) * In participants that are autoantibody seronegative i.e. not positive for anti-AChR and anti-MuSK antibodies and participants who are positive for anti-low-density lipoprotein receptor-related protein 4 antibodies (anti-LRP4) * Has a Screening and Baseline MG-ADL score more than or equal to (\>=) 6 with \>= 50 percentage (%) of the total score due to non-ocular symptoms. Screening and Baseline MG-ADL scores must be stable. The difference between the Screening and Baseline scores should not be more than 2 and there should be no reported MG exacerbation during the Screening period * If treated with oral corticosteroids: should be on a stable daily dose for at least 3 months prior to and during screening. In such case, the daily dose of oral steroids should not exceed 20 milligrams(mg)/day for prednisone/ prednisolone, 16 mg/day for methylprednisolone, 3 mg/day for dexamethasone, or 80 mg for hydrocortisone or equivalent doses for other corticosteroids. * If treated with acetylcholinesterase inhibitor should be on a stable daily dose (pyridostigmine dose ≤ 480 mg/day or neostigmine ≤ 300 mg/day) for at least 3 months prior to and during screening * Have a body weight \>= 40 kilograms * Other protocol defined inclusion criteria could apply Exclusion Criteria: * Immunologic disorder other than MG or any other condition requiring chronic oral, intravenous, intramuscular, or intraarticular corticosteroid therapy. Well-controlled thyroid disease, as per the Treating Investigator or the participants regular treating physician recorded in the source documents, is not exclusionary * Molecularly characterized or suspected congenital myasthenic syndrome, Lambert-Eaton myasthenic syndrome, inherited myopathy, muscular dystrophy, acquired myopathy or any other neurologic or systematic disease that mimics MG muscular weakness * Active, clinically significant viral, bacterial, or fungal infection, including brain MRI or chest X-ray findings consistent with signs of infection such as PML or TB, or any major episode of infection requiring hospitalization or treatment with parenteral anti-infectives within 8 weeks prior or during Screening, or completion of oral anti-infectives within 8 weeks prior or during Screening. Vaginal candidiasis, onychomycosis, and genital or oral herpes simplex virus considered by the Investigator to be sufficiently controlled would not be exclusionary * Has a history of or current diagnosis of active tuberculosis (TB) or is currently undergoing treatment for latent TB infection or has an untreated latent TB infection as determined by documented results within 3 months of the Screening Visit of a positive TB skin test . * Active malignancy, or history of cancer or signs of malignancy in any Screening assessment * Treatment with nonsteroidal immunosuppressants, used in gMG, such as azathioprine, mycophenolate mofetil, methotrexate, cyclosporine, cyclophosphamide, tacrolimus within 4 weeks prior to randomization * Treatment with FcRn or complement inhibitors (such as eculizumab, rozanolixizumab efgartigimod, ravulizumab, zilucoplan or nipocalimab) within 8 weeks prior to randomization * History of thymectomy within 6 months prior to Screening. * History of generalized seizures (except for history of febrile seizures during the participant's childhood). * Negative or indeterminate for Varicella Zoster Virus antibodies at screening * History of myasthenic crisis in the last 12 months prior to and during screening * History of recurrent infections (that is 3 or more infections per year documented in available source data) within the last 2 years * Discontinuation of treatment with any non-steroidal immunosuppressants used in gMG, such as azathioprine, mycophenolate mofetil, methotrexate, cyclosporine, cyclophosphamide, tacrolimus within the last 6 months prior to Screening * If treated with non-steroidal immunosuppressants for gMG, the dose at Screening higher than 50 mg/day for azathioprine, 500 mg/day for mycophenolate mofetil, 1 mg/day for tacrolimus, 50 mg/day for cyclosporine, 25 mg/day for cyclophosphamide, or 7.5 mg/week for methotrexate * Participation in clinical study of any investigational drug within 6 months, or 5 half-lives of the investigational drug used in the previous clinical study prior to randomization, whichever is longer. However, participants with any prior exposure to cladribine may not enter the study regardless of timing of exposure * Other protocol defined exclusion criteria could apply

NCT07787182Recruiting

A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

Healthy Volunteers · Alzheimer Disease · Amyloid · Plaque, Amyloid

Why this research matters

Original registry summary

The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the Clinical Research Unit (CRU). For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 25 weeks and will include a 3-day stay in the CRU.

Who may participate

Age
18 Years – 85 Years
Sex
All
Healthy volunteers
Yes
Study type
Interventional

Location

  • CenExel ACT, Anaheim, California, United States
  • Irvine Clinical Research, Irvine, California, United States
  • Collaborative Neuroscience Network - CNS, Los Alamitos, California, United States
All listed locations
  • Fortrea Clinical Research Unit, Daytona Beach, Florida, United States
  • K2 Medical Research - The Villages, Lady Lake, Florida, United States
  • K2 Medical Research, Maitland, Florida, United States
  • Charter Research, Orlando, Florida, United States
  • Progressive Medical Research, Port Orange, Florida, United States
  • Alzheimer's Research and Treatment Center, Stuart, Florida, United States
  • K2 Medical Research - Tampa, Tampa, Florida, United States
  • Charter Research, The Villages, Florida, United States
  • Accel Research Sites - NeuroStudies Clinical Research Unit, Decatur, Georgia, United States
  • QUEST Research Institute, Farmington Hills, Michigan, United States
  • Xuanwu Hospital Capital Medical University, Beijing, China
  • Peking University Third Hospital, Beijing, China
  • Huashan Hospital, Fudan University, Minhang District, China
  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • The University of Tokyo Hospital, Bunkyō City, Japan
  • National Center for Geriatrics and Gerontology, Ōbu, Japan
Key criteria · Original registry text

Inclusion Criteria: * Participants must meet eligibility criteria in the ATMP screening protocol before entry into the treatment study. Exclusion Criteria: * Have known allergies to LY4405094, related compounds (including remternetug), or any components of the formulation, including LY4405094. * Have known allergic reactions to adhesive or hydrogels or a family history of adhesive skin allergies.

NCT07723976Recruiting

A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE

Developmental and Epileptic Encephalopathy (DEE)

Why this research matters

Original registry summary

The efficacy, safety, and tolerability of CBD-OS have been evaluated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous sclerosis complex (TSC). The current JZP926-303 study is being conducted to evaluate the safety and efficacy of CBD-OS in participants with Developmental and Epileptic Encephalopathy (DEE).

Who may participate

Age
1 Year – Not specified
Sex
All
Healthy volunteers
No
Study type
Interventional

Location

  • University Of Alabama Birmingham, Birmingham, Alabama, United States
  • Barrow Institute (ESC), Phoenix, Arizona, United States
  • UC Irvine, Orange, California, United States
All listed locations
  • Sutter Health, Sacramento, California, United States
  • UC Davis Health Midtown Ambulatory Care Center, Sacramento, California, United States
  • Yale School Of Medicine (ESC), New Haven, Connecticut, United States
  • (DEECRN) Children's National Hospital Friendship Heights; Children's National Medical Center, Washington D.C., District of Columbia, United States
  • Pediatric Epilepsy & Neurology Specialists (PENS), Tampa, Florida, United States
  • Hawaii Pacific Neuroscience (HPN) Comprehensive Epilepsy Center, Honolulu, Hawaii, United States
  • Sinai Hospital of Baltimore, Baltimore, Maryland, United States
  • Mid Atlantic Epilepsy And Sleep Center (ESC), Bethesda, Maryland, United States
  • Hackensack Meridian Neuroscience Institute At JFK University Medical Center, Edison, New Jersey, United States
  • Northwell Health Division Of Pediatric Neurology (ESC), Lake Success, New York, United States
  • (DEECRN) Weill Cornell Medicine Pediatric Neurology, New York, New York, United States
  • Cincinnati Children's Hospital Medical Center (ESC), Cincinnati, Ohio, United States
  • (DEECRN) The Children's Hospital Of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
  • McGovern Medical School UT Physicianspediatric Neurology Texas Medical Center, Houston, Texas, United States
  • Seattle Children's Hospital, Seattle, Washington, United States
  • Queensland Children's Hospital, Brisbane, Australia
  • Monash Health (Monash Children's), Clayton, Australia
  • Royal Brisbane and Women's Hospital, Herston, Australia
  • Bayside (The Alfred), Melbourne, Australia
  • The Children's Hospital at Westmead, Melbourne, Australia
  • Austin Health Hospital, Melbourne, Australia
  • Sydney Children's Hospital, Randwick, Australia
  • Semmelweis Egyetem Altalanos Orvostudomanyi Kar Gyermekgyogyaszati Klinika, Budapest, Hungary
  • Flash Clinic, Budapest, Hungary
  • (EpiCARE)Orszagos Idegtudomanyi Intezet (Oiti) (National Institute Of Neurosurgery (NICN) Juhasz Pal Epilepszia Kozpont, Budapest, Hungary
  • (EpiCARE Center) IRCCS Istituto delle Scienze Neurologiche di Bologna, Bolognia, Italy
  • Ospedale dei Bambini, Brescia, Italy
  • Salesi Pediatric Hospital Aou Delle Marche Ancona, Cagliari, Italy
  • (EpiCARE Center) Istituto Giannina Gaslini IRCCS, Genova, Italy
  • (EpiCARE Center) ASST Santi Paolo E Carlo Ospedale San Paolo Polo Universitario Centro Regionale Per L Epilessia, Milan, Italy
  • ASST Fatebenefratelli Sacco-Ospedale Dei Bambini Vittore Buzzi, Milan, Italy
  • (EpiCARE Center) Ospedale Pediatrico Bambino Gesu - Ambulatorio di Neurologia dell Epilessia e Disturbi del Movimento, Roma, Italy
  • (EpiCARE Center) Universita Cattolica Del Sacro Cuore Policlinico Universitario Agostino Gemelli, Roma, Italy
  • (EpiCARE Center) Azienda Ospedaliera Universitaria Integrata Verona (Aoui) Ospedale Policlinico Giambattista Rossi Di Borgo Roma, Verona, Italy
  • Hospital Infantil Nino Jesus de Madrid, Madrid, Spain
  • Hospital Universitario Clinico San Carlos Madrid, Madrid, Spain
  • Hospital Materno Infantil De Malaga, Málaga, Spain
  • Clinica Universidad De Navarra Pamploma, Navarra, Spain
  • Hospital Navarra, Navarra, Spain
  • Centro De Neurologia Avanzada (CAN) Sevilla, Seville, Spain
Key criteria · Original registry text

Participants are eligible to be included in the study only if all the following criteria apply: 1. Is at least 1 year of age at the time of signing the informed consent/assent. 2. Meets the clinical phenotype for DEE as specified in the protocol. 3. Per the investigator, the underlying etiology contributes to developmental impairment and seizures. 4. Has had, or is willing to complete, confirmatory imaging and/or genetic testing to determine etiology of DEE. 5. Is currently receiving antiseizure intervention, such as treatment with a stable regimen of at least 1 ASM or an established intervention for epilepsy (eg, ketogenic diet or neurostimulation). 6. All medications or interventions for epilepsy have been stable for ≥ 28 days prior to starting the baseline period (Visit 2) with no planned changes to the regimen for the duration of the Double-blind Treatment Period. Participants are excluded from the study if any of the following criteria apply: 1. Has a concurrent, confirmed diagnosis of non-epileptic seizures or events that can confound the assessment of the efficacy measures, in the opinion of the investigator. 2. The etiology of the participant's seizures is a progressive neurologic disease. 3. Has known or suspected hypersensitivity to cannabinoids or any of the excipients of the study intervention, such as sesame oil. 4. Has an active central nervous system (CNS) infection, demyelinating disease, degenerative neurologic disease, or any CNS disease deemed to be progressive during the study that may confound the interpretation of the study results (including autoimmune encephalitis). 5. Is currently being treated with Epidiolex or recently received treatment with Epidiolex within 28 days prior to screening. 6. Has experienced a lack of efficacy and/or poor tolerability to an adequate treatment regimen of Epidiolex based on medical history and the clinical judgement of the investigator. Participants who discontinued treatment for reasons other than safety, tolerability, or lack of efficacy and previously received Epidiolex ≥ 28 days prior to starting the Baseline Period (Visit 2) may be eligible for the study after consultation with the medical monitor and/or sponsor representative. 7. Has been taking felbamate for less than 12 months prior to screening. Participants who are stable on felbamate for ≥ 12 months are eligible for inclusion.

NCT04550728Recruiting

Hybrid Robot+FES Stroke Rehabilitation

Stroke

Why this research matters

Original registry summary

The investigators have developed a novel robot-guided stretching under intelligent control and combine it with active movement training, which helped increase joint ROM, reduce spasticity and joint stiffness, increase muscle force output, and improve locomotion. However, for stroke survivors with sensorimotor impairment, their peripheral muscle may not sufficiently be recruited. Functional electrical stimulation (FES), has been shown its advantage to activate the peripheral muscles for people with neurological conditions. The investigators thus make a hybrid robot-FES rehabilitation system, combining the advantage of robot and FES technologies for stroke motor recovery. The investigators further would like to translate the technologies from lab to home-based training. Thus, the investigators will conduct a randomized, controlled, primarily home-based clinical trial using an ankle robot alone or combined with functional electrical stimulation (FES) to treat sensorimotor and locomotion impairments post-stroke.

Who may participate

Age
18 Years – 85 Years
Sex
All
Healthy volunteers
No
Study type
Interventional

Location

  • University of Maryland School of Medicine, Baltimore, Maryland, United States
Key criteria · Original registry text

Inclusion Criteria: * Age 18-85; * Able to ambulate at least 10 meters without human assistance, with or without an assistive device * ≥ 6 months post stroke; * having a caregiver to assist in training at home. Exclusion Criteria: * having expressive and receptive aphasia; * an inability to follow multi-step commands; * enrolled in another lower limb rehabilitation program; * having severe pain in the paralyzed lower-limb; * \>30º ankle plantar flexion contracture; * Having implanted electronic device such as a pacemaker, spinal cord, or deep brain stimulator because FES may potentially interfere with their functions.

NCT06976203Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Alzheimer's Disease

Why this research matters

Original registry summary

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

Who may participate

Age
60 Years – 85 Years
Sex
All
Healthy volunteers
No
Study type
Interventional

Location

  • Fullerton Neurology and Headache Center, Fullerton, California, United States
  • Irvine Clinical Research, Irvine, California, United States
  • Inglewood Clinical, Los Angeles, California, United States
All listed locations
  • Stanford Neuroscience Health Center, Palo Alto, California, United States
  • Local Institution - 0069, San Diego, California, United States
  • Research of the Rockies, Colorado Springs, Colorado, United States
  • Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States
  • Local Institution - 0086, Hallandale, Florida, United States
  • Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
  • K2 MEDICAL Research THE VILLAGES, Lady Lake, Florida, United States
  • Intercoastal Medical Group, Sarasota, Florida, United States
  • USF Health Byrd Alzheimer's Institute, Tampa, Florida, United States
  • Local Institution - 0129, The Villages, Florida, United States
  • Alzheimer's Research and Treatment Center, Wellington, Florida, United States
  • Great Lakes Clinical Trials - Andersonville, Chicago, Illinois, United States
  • Southern Illinois University School of Medicine, Springfield, Illinois, United States
  • Josephson Wallack Munshower Neurology, PC, Indianapolis, Indiana, United States
  • Boston Center for Memory, Newton, Massachusetts, United States
  • Local Institution - 0080, Watertown, Massachusetts, United States
  • QUEST Research Institute, Farmington Hills, Michigan, United States
  • Private Practice - Dr. Ronald Louis Schwartz, Hattiesburg, Mississippi, United States
  • Local Institution - 0119, Ridgewood, New Jersey, United States
  • The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States
  • Advanced Clinical Institute, West Long Branch, New Jersey, United States
  • Neurological Associates Albany, Albany, New York, United States
  • Dent Neurosciences Research Center, Inc, Amherst, New York, United States
  • University at Buffalo - UBMD Neurology, Buffalo, New York, United States
  • Local Institution - 0078, Lake Success, New York, United States
  • Keystone Clinical Studies, Plymouth Meeting, Pennsylvania, United States
  • Local Institution - 0081, Dallas, Texas, United States
  • Central Texas Neurology Consultants, PA, Round Rock, Texas, United States
  • Local Institution - 0076, Renton, Washington, United States
  • Hospital Italiano de Buenos Aires, ABB, Buenos Aires F.D., Argentina
  • Centro Médico Luquez, Córdoba, Córdoba Province, Argentina
  • Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI), Buenos Aires, Argentina
  • CEN Centro Especializado en Neurociencias, Córdoba, Argentina
  • Instituto Médico DAMIC, Córdoba, Argentina
  • Resolution Psychopharmacology Research Institute, Mendoza, Argentina
  • University of the Sunshine Coast Birtinya, Birtinya, Queensland, Australia
  • Local Institution - 0055, Herston (rbwh Grounds), Queensland, Australia
  • Griffith University - Gold Coast Campus, Southport, Queensland, Australia
  • Austin Health, Ivanhoe, Victoria, Australia
  • Local Institution - 0115, Fortaleza, Ceará, Brazil
  • Clinilive, Maringá, Paraná, Brazil
  • Ruschel Medicina e Pesquisa Clínica, Rio de Janeiro, Brazil
  • CPQuali Pesquisa Clínica, São Paulo, Brazil
  • Terveystalo Oulu, Oulu, North Ostrobothnia, Finland
  • Clinical Research Services Turku, Turku, Southwest Finland, Finland
  • CRST Helsinki Oy, Helsinki, Uusimaa, Finland
  • Terveystalo Kamppi, Helsinki, Finland
  • Itä-Suomen Yliopisto Kuopio, Kuopio, Finland
  • Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone, Marseille, Bouches-du-Rhône, France
  • Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau, Tours, Centre-Val de Loire, France
  • Centre Hospitalier Universitaire Toulouse - Cité de la Santé, Toulouse, Haute-Garonne, France
  • Centre Hospitalier Régional Universitaire de Lille - Hôpital Roger Salengro, Lille, Hauts-de-France, France
  • Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou, Rennes, Ille-et-Vilaine, France
  • Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes, Saint-Herblain, Loire-Atlantique, France
  • Centre Hospitalier Universitaire Régional de Nancy, Nancy, Meurthe-et-Moselle, France
  • Hospices Civils de Lyon - Hôpital Pierre Wertheimer, Bron, Rhône, France
  • Local Institution - 0017, Villefranche-sur-Saône, Rhône, France
  • Bordeaux University Hospital - Pellegrin, Bordeaux, France
  • Assistance Publique Hôpitaux de Paris - Groupe Hospitalier 10e - Hôpital Lariboisière, Paris, France
  • Hôpital Broca, Paris, France
  • Pitie Salpetriere University Hospital, Paris, France
  • Les Hôpitaux Universitaires de Strasbourg - Hôpital de la Robertsau, Strasbourg, France
  • Ludwig-Maximilians-Universität München, Munich, Bavaria, Germany
  • Universitätsmedizin Göttingen - Georg-August-Universität, Göttingen, Lower Saxony, Germany
  • Private Practice - Dr. Irma Schöll, Bad Homburg, Germany
  • Pharmakologisches Studienzentrum Chemnitz, Chemnitz, Germany
  • Universitaetsklinikum Koeln, Cologne, Germany
  • Universitaetsklinikum Ulm, Ulm, Germany
  • University Hospital of Patras, Pátrai, Achaḯa, Greece
  • University General Hospital "ATTIKON" - General Hospital of West Attica "H AGIA VARVARA", Chaïdári, Attikí, Greece
  • Hygeia Hospital, Marousi, Attikí, Greece
  • Local Institution - 0059, Ioannina, Ioánnina, Greece
  • AHEPA University General Hospital of Thessaloniki, Thessaloniki, Greece
  • University of Naples Federico II, Naples, Campania, Italy
  • Azienda Ospedaliero Universitaria Policlinico Riuniti di Foggia, Foggia, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore, Roma, Italy
  • Inage Neurology and Memory Clinic, Inage, Chiba, Japan
  • Local Institution - 0123, Matsudo, Chiba, Japan
  • Imon Yukari Neurology Clinic, Hiroshima, Hiroshima, Japan
  • Kagawa University Hospital, Kita-gun, Kagawa-ken, Japan
  • Local Institution - 0125, Kamakura, Kanagawa, Japan
  • Kokankai Kokan Clinic, Kawasaki, Kanagawa, Japan
  • Nippon Medical School Musashi Kosugi Hospital, Kawasaki, Kanagawa, Japan
  • Ina Central Hospital, Ina, Nagano, Japan
  • National Hospital Organization Niigata Hospital, Kashiwazaki, Niigata, Japan
  • Katayama Medical Clinic, Kurashiki, Okayama-ken, Japan
  • Local Institution - 0131, Hirakata, Osaka, Japan
  • Tominaga Clinic, Osaka, Osaka, Japan
  • National Hospital Organization Hizen Psychiatric Center, Yoshinogari-cho, Kanzaki-gun, Saga-ken, Japan
  • Local Institution - 0037, Wako, Saitama, Japan
  • Wako Hospital, Wako, Saitama, Japan
  • Local Institution - 0107, Kyoto, Japan
  • Brain Research Center Den Bosch B.V., 's-Hertogenbosch, North Brabant, Netherlands
  • Brain Research Center, Amsterdam, North Holland, Netherlands
  • Brain Research Center Zwolle, Zwolle, Overijssel, Netherlands
  • Instytut Zdrowia Dr Boczarska Jedynak, Oświęcim, Lesser Poland Voivodeship, Poland
  • Penta Hospitals Przychodnie, Wrocław Wejherowska, Wroclaw, Lower Silesian Voivodeship, Poland
  • Local Institution - 0108, Lublin, Lublin Voivodeship, Poland
  • EMC Silesia sp. z o.o., Katowice, Silesian Voivodeship, Poland
  • Campus Neurológico Sénior, Torres Vedras, Lisbon District, Portugal
  • Unidade Local de Saude de Matosinhos, Matosinhos Municipality, Porto District, Portugal
  • Hospital de Braga, Braga, Portugal
  • Unidade Local de Saúde de Coimbra, E.P.E., Coimbra, Portugal
  • Centro Hospitalar do Alto Ave - Hospital Senhora da Oliveira, Guimarães, Portugal
  • Centro Hospitalar do Porto - Hospital de Santo António, Porto, Portugal
  • SCB Research Center, Bayamón, Puerto Rico
  • Prof. Dr. Alexandru Obregia Psychiatry Hospital, Bucharest, Bucharest, Romania
  • Prof. Dr. Alexandru Obregia Psychiatry Hospital, Bucharest, Bucharest, Romania
  • Brainaxy Clinic, Constanța, Constanța County, Romania
  • Local Institution - 0042, Bucharest, Romania
  • Spitalul de Psihiatrie și Neurologie Brașov, Sanpetru /Brasov, Romania
  • Fundació ACE, Barcelona, Barcelona [Barcelona], Spain
  • Policlinica Gipuzkoa, Donostia / San Sebastian, Basque Country, Spain
  • Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
  • Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcón, Madrid, Spain
  • Hospital Universitario Doctor Peset, Valencia, Valenciana, Comunitat, Spain
  • Complejo Hospitalario Ruber Juan Bravo, Madrid, Spain
  • Hospital Universitario 12 de Octubre, Madrid, Spain
  • NIHR Manchester Clinical Research Facility, Manchester, England, United Kingdom
  • The Maudsley Hospital, London, London, City of, United Kingdom
  • Western General Hospital, Edinburgh, Midlothian, United Kingdom
  • Warneford Hospital, Oxford, Oxfordshire, United Kingdom
  • Re:Cognition Health - Birmingham, Birmingham, United Kingdom
  • Leeds and York Partnership NHS Foundation Trust, Leeds, United Kingdom
  • NeuroClin Glasgow, Motherwell, United Kingdom
  • Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
Key criteria · Original registry text

Inclusion Criteria: * Participants must have a confirmed diagnosis of Alzheimer's disease (AD), specifically at the mild (stage 4) or moderate (stage 5) dementia stages, as defined by the National Institute on Aging and Alzheimer's Association (NIA-AA) core clinical criteria. The diagnosis of AD pathology must be confirmed through the 2024 revised NIA-AA Workgroup criteria using a stepwise diagnostic approach. * Participants must have an Mini-Mental State Examination (MMSE) score ranging from 12 through 22, inclusive, at the time of screening. * Participants must have a designated caregiver who maintains adequate contact (around 10 hours per week or more) and is willing to attend all study visits. The caregiver must also be responsible for reporting on the participant's condition, overseeing medication compliance, and consenting to their involvement in both their own and the participant's study-related activities. * Participants on acetyl choline esterase inhibitors (AChEIs) and/or memantine, must have been on a stable dosage for at least 12 weeks prior to screening, and agree to maintain this stable dose for the study duration. Exclusion Criteria: Participants must not present with any significant or severe medical conditions that could compromise their safety, the ability to comply with or complete the study, or the integrity of the study results. This includes any grade of hepatic impairment, urinary retention, active biliary disease, moderate-severe renal impairment (eGFR of \<50 mL/min), and unstable hypertension or tachycardia. * Participants must not have any primary psychiatric diagnoses such as major depression, schizoaffective disorder, or bipolar disorder, and those with severe psychiatric symptoms that could complicate the interpretation of treatment effects, impair cognitive assessment, or impact study completion. * Participants must not have a history of schizophrenia or other chronic psychosis, as well as those who have previously been exposed to KarXT or are currently undergoing treatment with disease-modifying anti-amyloid therapies for AD within the past 6 months prior to screening. * Participants must not have significant pathological findings on brain magnetic resonance imaging (MRI) at screening that could affect safety or interfere with study procedures. * Other protocol-defined Inclusion/Exclusion criteria apply.

NCT01273129Recruiting

Surgery as a Treatment for Medically Intractable Epilepsy

Epilepsy · Epilepsy, Temporal Lobe · Partial Epilepsy

Why this research matters

Original registry summary

Background: \- Drug resistant epilepsy is the term used to describe epilepsy that cannot be controlled by medication. Many people whose seizures do not respond to medication will respond to surgical treatment, relieving seizures completely or almost completely in one-half to two-thirds of patients who qualify for surgery. The tests and surgery performed as part of this treatment are not experimental, but researchers are interested in using the data collected as part of routine standard epilepsy care to better understand epilepsy and its treatment. Objectives: \- To use surgery as a treatment for drug resistant epilepsy in children and adults. Eligibility: \- Children and adults at least 8 years of age who have simple or complex partial seizures (seizures that come from one area of the brain) that have not responded to medication, and who are willing to have brain surgery to treat their medically intractable epilepsy. Design: * Participants will be screened with a medical history, physical examination, and neurological examination. Imaging studies, including magnetic resonance imaging and computer-assisted tomography (CT), may also be conducted as part of the screening. Participants who do not need surgery or whose epilepsy cannot be treated surgically will follow up with a primary care physician or neurologist and will not need to return to the National Institutes of Health for this study. * Prior to the surgery, participants will have the following procedures to provide information on the correct surgical approach. * Video electroencephalography monitoring to measure brain activity during normal activities within a 24-hour period. Three to four 15-minute breaks are allowed within this period. * Electrodes placed directly in the brain or on the surface of the brain to measure brain activities and determine the part of the brain that is responsible for the seizures (seizure focus). * Participants will have a surgical procedure at the site of their seizure focus. Brain lesions, abnormal blood vessels, tumors, infections, or other areas of brain abnormality will be either removed or treated in a way that will stop or help prevent the spread of seizures without affecting irreplaceable brain functions, such as the ability to speak, understand, move, feel, or see. * Participants will return for outpatient visits and brain imaging studies 2 months, 1 year, and 2 years after surgery.

Who may participate

Age
8 Years – 99 Years
Sex
All
Healthy volunteers
No
Study type
Observational

Location

  • National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Key criteria · Original registry text

* INCLUSION CRITERIA: To be eligible for entry into the study, candidates must: 1\. Be 8 years of age or older with drug resistant epilepsy or tumor related epilepsy. EXCLUSION CRITERIA: Candidates will be excluded if they: 1\. Are unable or unwilling to give informed consent, or have a parent able to provide informed consent if a minor, to the research procedures.

NCT07099053Recruiting

PET Imaging in the Baltimore Longitudinal Study of Aging (BLSA)

Aging

Why this research matters

Original registry summary

Background: Some people experience cognitive decline as they age. That is, they lose memory, problem-solving, and other mental abilities. Amyloids are groups of proteins that develop in the brain and increase in number as people age. Researchers want to use imaging scans to track amyloids in people s brains over time. Their goal is to find out if any changes are related to cognitive decline or other medical issues. Objective: To learn how amyloids may affect brain structure and function as people age. Eligibility: People aged 55 years and older who are enrolled in the Baltimore Longitudinal Study of Aging. Design: Participants will have imaging scans and other tests every 1 to 4 years, depending on their age. Those 80 and older will be scanned yearly. These scans will be done during regular BLSA visits. The scans will be positron emission tomography and computed tomography (PET CT). Participants will be given fluid through a tube inserted into a vein in their arm. The fluid is a tracer that will cause the amyloids to light up in the images. Then they will lie on a bed with their head inside a PET CT scanner. They will lie still for about 30 minutes. Participants will have tests to assess their memory and other mental skills. They will answer questions about their mood and daily life. These tests will take about 40 minutes to complete; they may be done in person or by phone. Participants will give a contact number for someone who can answer questions about the participant s daily routine. These questions may be answered in person or by phone. Participants will be in this study for 5 years.

Who may participate

Age
55 Years – 110 Years
Sex
All
Healthy volunteers
Yes
Study type
Observational

Location

  • National Institute of Aging, Clinical Research Unit, Baltimore, Maryland, United States
Key criteria · Original registry text

* INCLUSION/EXCLUSION CRITERIA: * Participants are men and women 55 years and older drawn from the BLSA sample and thus, represent the gender/ethnic characteristics of this study group. Enrollment is defined as the initial imaging session of the planned longitudinal study. * Inclusion criteria. BLSA participants who do not meet exclusion criteria and have had or agreed to have an MRI under the BLSA study. * Participants who lack capacity to consent will not be enrolled in the study. If the participant loses capacity to consent over the course of follow-up they will be removed from the study. Competency to consent is assessed as part of the BLSA visit and we will not include people who are not competent to provide consent. EXCLUSION CRITERIA: * Preexisting central nervous system diseases * Weight over 300 lbs. * Active metastatic cancer (except basal cell cancer) * Implanted electronic hearing devices * Breast Cancer with radiation treatment * Lymphoma * Pacemaker * Brain tumor * Shrapnel * Schizophrenia * Bipolar disorder * Epilepsy * Language barrier that makes it difficult to understand participant. * Aneurisms greater than 3mm * Aneurysm clips * Parkinson s disease/PD medications * Huntington s disease * Severe Endocrinopathy- treated thyroid conditions ok; treated, controlled diabetes ok. (exclude HbA1c over 8 which is poorly controlled diabetes) * Diagnosis of dementia or mild cognitive impairment * Younger than 55 years of age * Pregnancy * Ineligible for MRI * History of stroke or documented TIAs requiring hospitalization * Known brain vascular malformations or adenomas * History of significant radiation exposure * Those with a Blessed score of 4 or more with the BLSA will be reviewed at a research diagnostic case conference to rule out dementia diagnoses prior to enrollment. * Participants undergoing chronic treatment with a CYP1A2 inducer will be ineligible for Tauklarify PET, but this does not constitute an exclusion criterion for Neuraceq PET.

NCT06966700Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Breast Neoplasms · Triple Negative Breast Neoplasms · HR Low-Positive/HER2-Negative Breast Neoplasms

Why this research matters

Original registry summary

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone. Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab, and chemotherapy: * Have fewer cancer cells found in the tumors and lymph nodes removed during surgery compared to those who receive only pembrolizumab and chemotherapy * Live longer without the cancer growing, spreading, or coming back compared to people who receive only pembrolizumab with chemotherapy

Who may participate

Age
18 Years – Not specified
Sex
All
Healthy volunteers
No
Study type
Interventional

Location

  • Banner MD Anderson Cancer Center ( Site 0066), Gilbert, Arizona, United States
  • Mayo Clinic Cancer Center ( Site 0034), Phoenix, Arizona, United States
  • University of Arizona Cancer Center ( Site 0035), Tucson, Arizona, United States
All listed locations
  • Roy and Patricia Disney Family Cancer Center ( Site 0055), Burbank, California, United States
  • Community Cancer Institute ( Site 0100), Clovis, California, United States
  • Providence Medical Foundation ( Site 0080), Fullerton, California, United States
  • MemorialCare Health System - Long Beach Medical Center ( Site 9556), Long Beach, California, United States
  • El Camino Hospital Cancer Center ( Site 0096), Mountain View, California, United States
  • Hoag Memorial Hospital Presbyterian ( Site 0010), Newport Beach, California, United States
  • Helios Clinical Research ( Site 0061), Whittier, California, United States
  • Intermountain Health Cancer Center Saint Joseph ( Site 0062), Denver, Colorado, United States
  • Rocky Mountain Cancer Centers (RMCC) ( Site 8006), Denver, Colorado, United States
  • Intermountain Health St. Mary's Regional Hospital ( Site 0054), Grand Junction, Colorado, United States
  • AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0044), Altamonte Springs, Florida, United States
  • Florida Cancer Specialists - South ( Site 7004), Fort Myers, Florida, United States
  • Bioresearch Partner ( Site 0072), Hialeah, Florida, United States
  • Mayo Clinic Hospital ( Site 0013), Jacksonville, Florida, United States
  • Florida Cancer Specialists - North ( Site 7002), St. Petersburg, Florida, United States
  • City of Hope Cancer Center - Atlanta ( Site 0102), Newnan, Georgia, United States
  • Southern Illinois Hospital Services ( Site 9554), Carterville, Illinois, United States
  • Fort Wayne Medical Oncology and Hematology ( Site 0084), Fort Wayne, Indiana, United States
  • Franciscan Health ( Site 0077), Indianapolis, Indiana, United States
  • Ochsner Clinic Foundation ( Site 0021), New Orleans, Louisiana, United States
  • Louisiana State University Health Sciences Shreveport ( Site 0053), Shreveport, Louisiana, United States
  • New England Cancer Specialists ( Site 0051), Westbrook, Maine, United States
  • Mercy Medical Center - Baltimore ( Site 0015), Baltimore, Maryland, United States
  • Massachusetts General Hospital Cancer Center ( Site 0091), Boston, Massachusetts, United States
  • Dana Farber Cancer Institute ( Site 0090), Boston, Massachusetts, United States
  • Saint Luke's Cancer Institute ( Site 0059), Kansas City, Missouri, United States
  • Washington University Siteman Cancer Center ( Site 0031), St Louis, Missouri, United States
  • Cancer Partners of Nebraska ( Site 0068), Lincoln, Nebraska, United States
  • Optum Care Cancer Center ( Site 0050), Las Vegas, Nevada, United States
  • Renown Regional Medical Center ( Site 0041), Reno, Nevada, United States
  • Hackensack Univ Medical Center (HUMC) ( Site 0007), Hackensack, New Jersey, United States
  • Rutgers Cancer Institute of New Jersey ( Site 0076), New Brunswick, New Jersey, United States
  • Altru Health System ( Site 0057), Grand Forks, North Dakota, United States
  • Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027), Cincinnati, Ohio, United States
  • Northwest Cancer Specialists (Compass Oncology) ( Site 8010), Tigard, Oregon, United States
  • Medical University of South Carolina-Hollings Cancer Center ( Site 0016), Charleston, South Carolina, United States
  • St Francis Cancer Center ( Site 0093), Greenville, South Carolina, United States
  • Avera McKennan Hospital ( Site 0002), Sioux Falls, South Dakota, United States
  • Avera Cancer Institute - Yankton ( Site 0089), Yankton, South Dakota, United States
  • Tennessee Cancer Specialists ( Site 7001), Knoxville, Tennessee, United States
  • SCRI Oncology Partners ( Site 7005), Nashville, Tennessee, United States
  • Nashville General Hospital ( Site 0017), Nashville, Tennessee, United States
  • Vanderbilt-Ingram Cancer Center ( Site 0038), Nashville, Tennessee, United States
  • Hendrick Medical Center ( Site 0009), Abilene, Texas, United States
  • Texas Oncology - DFW ( Site 8009), Dallas, Texas, United States
  • UT Southwestern ( Site 0092), Dallas, Texas, United States
  • Texas Oncology - Northeast Texas ( Site 8002), Flower Mound, Texas, United States
  • JPS Oncology and Infusion Center ( Site 0083), Fort Worth, Texas, United States
  • Kelsey-Seybold Clinic ( Site 0042), Houston, Texas, United States
  • Kelsey-Seybold Clinic ( Site 0088), Houston, Texas, United States
  • Oncology Consultants P.A. ( Site 0073), Houston, Texas, United States
  • Texas Tech University Health Sciences Center ( Site 0087), Lubbock, Texas, United States
  • Texas Oncology - San Antonio ( Site 8004), San Antonio, Texas, United States
  • Intermountain Medical Center ( Site 0074), Murray, Utah, United States
  • Bon Secours Cancer Institute at St. Francis ( Site 0048), Midlothian, Virginia, United States
  • Virginia Oncology Associates (VOA) ( Site 8008), Norfolk, Virginia, United States
  • Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 8005), Roanoke, Virginia, United States
  • Fred Hutchinson Cancer Center ( Site 0069), Seattle, Washington, United States
  • Cancer Care Northwest ( Site 0003), Spokane, Washington, United States
  • Northwest Medical Specialties, PLLC ( Site 0067), Tacoma, Washington, United States
  • University of Wisconsin-Madison ( Site 0024), Madison, Wisconsin, United States
  • Instituto de Investigaciones Clinicas Mar del Plata ( Site 6008), Mar del Plata, Buenos Aires, Argentina
  • Hospital Italiano de Buenos Aires-ginecology ( Site 6003), Buenos Aires, Buenos Aires F.D., Argentina
  • Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 6005), Buenos Aires, Buenos Aires F.D., Argentina
  • Fundacion Ars Medica ( Site 6004), San Salvador de Jujuy, Jujuy Province, Argentina
  • Sanatorio Parque ( Site 6002), Rosario, Santa Fe Province, Argentina
  • Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L ( Site 6006), San Miguel de Tucumán, Tucumán Province, Argentina
  • Sanatorio Finochietto ( Site 6007), Buenos Aires, Argentina
  • Sanatorio Allende - Nueva Córdoba ( Site 6000), Córdoba, Argentina
  • Sanatorio de la Cañada - Córdoba ( Site 6001), Córdoba, Argentina
  • Chris O'Brien Lifehouse ( Site 1206), Camperdown, New South Wales, Australia
  • Macquarie University ( Site 1203), North Ryde, New South Wales, Australia
  • Westmead Hospital ( Site 1200), Westmead, New South Wales, Australia
  • Monash Health ( Site 1201), Clayton, Victoria, Australia
  • Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman ( Site 3204), Liège, Liege, Belgium
  • Jessa Ziekenhuis ( Site 3200), Hasselt, Limburg, Belgium
  • AZORG Campus Aalst-Moorselbaan ( Site 3201), Aalst, Oost-Vlaanderen, Belgium
  • UZ Gent ( Site 3202), Ghent, Oost-Vlaanderen, Belgium
  • CHU UCL Namur/Site Sainte Elisabeth ( Site 3203), Namur, Belgium
  • PRONUTRIR ( Site 6120), Fortaleza, Ceará, Brazil
  • Hospital Araújo Jorge ( Site 6100), Goiânia, Goiás, Brazil
  • Liga Norte Riograndense Contra o Câncer ( Site 6111), Natal, Rio Grande do Norte, Brazil
  • Associação Hospitalar Beneficente São Vicente de Paulo ( Site 6115), Passo Fundo, Rio Grande do Sul, Brazil
  • Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 6102), Porto Alegre, Rio Grande do Sul, Brazil
  • Hospital São Lucas da PUCRS ( Site 6103), Porto Alegre, Rio Grande do Sul, Brazil
  • Clínica de Oncologia Reichow ( Site 6112), Blumenau, Santa Catarina, Brazil
  • Fundação Pio XII - Hospital de Câncer de Barretos ( Site 6108), Barretos, São Paulo, Brazil
  • Hospital de Base de São José do Rio Preto ( Site 6101), São José do Rio Preto, São Paulo, Brazil
  • INCA Hospital do Câncer III ( Site 6107), Rio de Janeiro, Brazil
  • BC Cancer - Surrey ( Site 0217), Surrey, British Columbia, Canada
  • BC Cancer Vancouver ( Site 0218), Vancouver, British Columbia, Canada
  • NL Health Services ( Site 0232), St. John's, Newfoundland and Labrador, Canada
  • Royal Victoria Regional Health Centre ( Site 0233), Barrie, Ontario, Canada
  • Health Sciences North ( Site 0234), Greater Sudbury, Ontario, Canada
  • Lakeridge Health ( Site 0225), Oshawa, Ontario, Canada
  • The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0209), Ottawa, Ontario, Canada
  • Sault Area Hospital ( Site 0226), Sault Ste. Marie, Ontario, Canada
  • Princess Margaret Cancer Centre ( Site 0208), Toronto, Ontario, Canada
  • Centre Hospitalier de l'Université de Montréal ( Site 0201), Montreal, Quebec, Canada
  • Jewish General Hospital ( Site 0200), Montreal, Quebec, Canada
  • McGill University Health Centre ( Site 0202), Montreal, Quebec, Canada
  • CHU de Quebec Universite Laval - Hopital du Saint-Sacrement ( Site 0203), Québec, Quebec, Canada
  • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0206), Sherbrooke, Quebec, Canada
  • Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec ( Site 0204), Trois-Rivières, Quebec, Canada
  • Allan Blair Cancer Centre ( Site 0227), Regina, Saskatchewan, Canada
  • Centro de Estudios Clínicos SAGA ( Site 6205), Santiago, Region M. de Santiago, Chile
  • Fundación Arturo López Pérez ( Site 6200), Santiago, Region M. de Santiago, Chile
  • Bradfordhill ( Site 6202), Santiago, Region M. de Santiago, Chile
  • ONCOCENTRO APYS ( Site 6204), Viña del Mar, Valparaiso, Chile
  • Anhui Provincial Cancer Hospital ( Site 2234), Hefei, Anhui, China
  • Beijing Cancer Hospital ( Site 2201), Beijing, Beijing Municipality, China
  • The First Affiliated hospital of Xiamen University-Breast Surgery ( Site 2224), Xiamen, Fujian, China
  • Guangdong Maternity and Child Health Care Hospital ( Site 2251), Guangzhou, Guangdong, China
  • Jiangmen Central Hospital ( Site 2243), Jiangmen, Guangdong, China
  • Liuzhou People's Hospital ( Site 2259), Liuzhou, Guangxi, China
  • Guangxi Medical University Affiliated Tumor Hospital ( Site 2223), Nanning, Guangxi, China
  • Xingtai People's Hospital ( Site 2260), Xingtai, Hebei, China
  • Harbin Medical University Cancer Hospital ( Site 2204), Haerbin, Heilongjiang, China
  • Henan Cancer Hospital ( Site 2238), Zhengzhou, Henan, China
  • Wuhan Union Hospital ( Site 2239), Wuhan, Hubei, China
  • Renmin Hospital of Wuhan University ( Site 2236), Wuhan, Hubei, China
  • Hunan Cancer Hospital ( Site 2232), Changsha, Hunan, China
  • Xiangya Hospital of Central South University ( Site 2225), Changsha, Hunan, China
  • Jiangsu Province Hospital ( Site 2216), Nanjing, Jiangsu, China
  • Nanjing Drum Tower Hospital ( Site 2217), Nanjing, Jiangsu, China
  • The Third Hospital Of Nanchang ( Site 2218), Nanchang, Jiangxi, China
  • The First Hospital Of Jilin University ( Site 2207), Changchun, Jilin, China
  • The First Affiliated Hospital of Xi'an Jiaotong University ( Site 2203), Xi'an, Shaanxi, China
  • Jinan Central Hospital ( Site 2249), Jinan, Shandong, China
  • Shandong Cancer Hospital ( Site 2205), Jinan, Shandong, China
  • LinYi Cancer Hospital ( Site 2248), Linyi, Shandong, China
  • Fudan University Shanghai Cancer Center ( Site 2209), Shanghai, Shanghai Municipality, China
  • Deyang City People's Hospital ( Site 2244), Deyang, Sichuan, China
  • The Second People's Hospital of Neijiang ( Site 2242), Neijiang, Sichuan, China
  • Xinjiang Medical University Cancer Hospital - Urumqi ( Site 2230), Ürümqi, Xinjiang, China
  • Yunnan Province Cancer Hospital ( Site 2226), Kunming, Yunnan, China
  • The Second Affiliated Hospital Zhejiang University School of Medicine ( Site 2212), Hangzhou, Zhejiang, China
  • Zhejiang Cancer Hospital ( Site 2211), Hangzhou, Zhejiang, China
  • Zhejiang Provincial People's Hospital ( Site 2215), Hangzhou, Zhejiang, China
  • Promotora Médica Las Américas S.A. ( Site 6302), Medellín, Antioquia, Colombia
  • FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 6311), Bogotá, Bogota D.C., Colombia
  • Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 6309), Bogotá, Bogota D.C., Colombia
  • IMAT S.A.S ( Site 6300), Montería, Departamento de Córdoba, Colombia
  • Oncologos del Occidente ( Site 6303), Pereira, Risaralda Department, Colombia
  • Fundación Valle del Lili ( Site 6308), Cali, Valle del Cauca Department, Colombia
  • Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 3400), Brno, Brno-mesto, Czechia
  • Nemocnice AGEL Novy Jicin a.s.-Oddeleni radioterapie a onkologie ( Site 3401), Nový Jičín, Moravian-Silesian Region, Czechia
  • Fakultni nemocnice Hradec Kralove-Klinika onkologie a radioterapie ( Site 3403), Hradec Králové, Czechia
  • Krajska nemocnice Liberec a.s.-Komplexni onkologicke centrum ( Site 3404), Liberec, Czechia
  • Oulun yliopistollinen sairaala ( Site 3603), Oulu, North Ostrobothnia, Finland
  • Tampereen ylipistollinen sairaala ( Site 3601), Tampere, Pirkanmaa, Finland
  • Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 3600), Helsinki, Uusimaa, Finland
  • Institut Paoli Calmettes. ( Site 3906), Marseille, Bouches-du-Rhone, France
  • Centre Georges Francois Leclerc ( Site 3902), Dijon, Bourgogne-Franche-Comté, France
  • Institut Curie - site Saint-Cloud ( Site 3909), Saint-Cloud, Hauts-de-Seine, France
  • Centre de Cancerologie du Grand Montpellier ( Site 3910), Montpellier, Herault, France
  • Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 3900), Rennes, Ille-et-Vilaine, France
  • centre hospitalier lyon sud ( Site 3901), Pierre-Bénite, Rhone, France
  • CHU d'Amiens-Picardie - Hôpital Sud ( Site 3908), Amiens, Somme, France
  • HENRI MONDOR HOSPITAL ( Site 3904), Créteil, Val-de-Marne, France
  • Institut Curie ( Site 3903), Paris, France
  • Universitaetsklinik Erlangen ( Site 4001), Erlangen, Bavaria, Germany
  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen ( Site 4015), Munich, Bavaria, Germany
  • St. Vincenz-Krankenhaus Frauen- und Kinderklinik ( Site 4003), Paderborn, North Rhine-Westphalia, Germany
  • InVO Institut für Versorgungsforschung in der Onkologie ( Site 4009), Koblenz, Rhineland-Palatinate, Germany
  • CaritasKlinikum Saarbruecken St. Theresia ( Site 4014), Saarbrücken, Saarland, Germany
  • Helios Klinikum Berlin-Buch ( Site 4008), Berlin, Germany
  • General Hospital of Athens - Laiko ( Site 4104), Athens, Attica, Greece
  • Aretaieio Hospital Oncology Unit ( Site 4101), Athens, Attica, Greece
  • Metropolitan Hospital ( Site 4102), Athens, Attica, Greece
  • ATHENS MEDICAL CENTER ( Site 4100), Marousi, Attica, Greece
  • European Interbalkan Medical Center ( Site 4103), Thessaloniki, Greece
  • MEDI-K ( Site 6400), Guatemala City, Guatemala
  • CELAN,S.A ( Site 6401), Guatemala City, Guatemala
  • INTEGRA Cancer Institute ( Site 6404), Guatemala City, Guatemala
  • Onco Go, S.A ( Site 6402), Guatemala City, Guatemala
  • Oncomedica ( Site 6405), Guatemala City, Guatemala
  • Asociacion Española de Beneficencia ( Site 6403), Guatemala City, Guatemala
  • Hong Kong United Oncology Centre ( Site 1304), Jordan, Hong Kong
  • Queen Mary Hospital ( Site 1300), Pokfulam, Hong Kong
  • Prince of Wales Hospital ( Site 1301), Shatin, Hong Kong
  • Tuen Mun Hospital ( Site 1303), Tuenmen, Hong Kong
  • Borsod-Abaúj-Zemplén Vármegyei Központi Kórház És Egyetemi Oktatókórház ( Site 4208), Miskolc, Borsod-Abauj Zemplen county, Hungary
  • Bacs-Kiskun Varmegyei Oktatokorhaz-Onkoradiologiai Kozpont ( Site 4207), Kecskemét, Bács-Kiskun county, Hungary
  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Onkoterapias Klinika ( Site 4202), Szeged, Csongrád megye, Hungary
  • Zala Vármegyei Szent Rafael Kórház-Onkológiai osztály ( Site 4206), Zalaegerszeg, Zala County, Hungary
  • Országos Onkológiai Intézet-B-Belgyógyászati Onkológiai Osztály ( Site 4204), Budapest, Hungary
  • Tata Memorial Hospital [M] ( Site 1400), Mumbai, Maharashtra, India
  • Apollo Hospital ( Site 1404), Mumbai, Maharashtra, India
  • Ruby Hall Clinic ( Site 1402), Pune, Maharashtra, India
  • All India Institute of Medical Sciences ( Site 1406), New Delhi, National Capital Territory of Delhi, India
  • Basavatarakam Indo American Cancer Hospital & Research Institute ( Site 1408), Hyderabad, Telangana, India
  • Rambam Health Care Campus ( Site 4400), Haifa, Israel
  • Meir Medical Center. ( Site 4403), Kfar Saba, Israel
  • Sheba Medical Center ( Site 4401), Ramat Gan, Israel
  • Yitzhak Shamir Medical Center. ( Site 4404), Tsrifin, Israel
  • Fondazione IRCCS San Gerardo dei Tintori ( Site 4513), Monza, Lombardy, Italy
  • Azienda USL Toscana Nord Ovest_Ospedale Civile di Livorno ( Site 4503), Livorno, Tuscany, Italy
  • Azienda Ospedaliero Universitaria delle Marche ( Site 4509), Ancona, Italy
  • ASST Papa Giovanni XXIII ( Site 4511), Bergamo, Italy
  • IRCCS Azienda Ospedaliera Metropolitana ( Site 4508), Genova, Italy
  • Ospedale San Raffaele di Milano ( Site 4515), Milan, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 4501), Milan, Italy
  • Istituto Oncologico Veneto IRCCS ( Site 4505), Padova, Italy
  • Azienda Ospedaliero Universitaria Pisana ( Site 4506), Pisa, Italy
  • Arcispedale Santa Maria Nuova ( Site 4510), Reggio Emilia, Italy
  • Istituto Nazionale Tumori Regina Elena ( Site 4512), Roma, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 4500), Roma, Italy
  • Nagoya City University Hospital ( Site 2310), Nagoya, Aichi-ken, Japan
  • National Hospital Organization Shikoku Cancer Center ( Site 2319), Matsuyama, Ehime, Japan
  • National Hospital Organization Hokkaido Cancer Center ( Site 2300), Sapporo, Hokkaido, Japan
  • Kanazawa Medical University Hospital ( Site 2321), Kahoku-gun, Ishikawa-ken, Japan
  • Kanagawa Cancer Center ( Site 2308), Yokohama, Kanagawa, Japan
  • Mie University Hospital ( Site 2312), Tsu, Mie-ken, Japan
  • Naha Nishi Clinic ( Site 2320), Naha, Okinawa, Japan
  • Kansai Medical University Hospital ( Site 2317), Hirakata, Osaka, Japan
  • Kindai University Hospital ( Site 2316), Sakai, Osaka, Japan
  • The University of Osaka Hospital ( Site 2314), Suita, Osaka, Japan
  • Shizuoka Cancer Center ( Site 2309), Sunto-gun, Shizuoka, Japan
  • National Cancer Center Hospital ( Site 2305), Chūō, Tokyo, Japan
  • Toranomon Hospital ( Site 2307), Minato, Tokyo, Japan
  • Showa Medical University Hospital ( Site 2306), Shinagawa, Tokyo, Japan
  • Akita University Hospital ( Site 2302), Akita, Japan
  • Chiba Cancer Center ( Site 2303), Chiba, Japan
  • Fukushima Medical University Hospital ( Site 2301), Fukushima, Japan
  • Hiroshima City Hiroshima Citizens Hospital ( Site 2318), Hiroshima, Japan
  • Kumamoto Shinto General Hospital ( Site 2322), Kumamoto, Japan
  • Kyoto University Hospital ( Site 2313), Kyoto, Japan
  • Nakagami Hospital ( Site 2323), Okinawa, Japan
  • National Hospital Organization Osaka National Hospital ( Site 2315), Osaka, Japan
  • University Malaya Medical Centre. ( Site 1503), Lembah Pantai, Kuala Lumpur, Malaysia
  • Hospital Pulau Pinang ( Site 1502), George Town, Pulau Pinang, Malaysia
  • National Cancer Institute ( Site 1501), Putrajaya, Putrajaya, Malaysia
  • Sarawak General Hospital ( Site 1504), Kuching, Sarawak, Malaysia
  • Pantai Hospital Kuala Lumpur ( Site 1500), Kuala Lumpur, Malaysia
  • Bowen Icon Cancer Centre ( Site 1001), Crofton Downs, Wellington Region, New Zealand
  • Auckland City Hospital ( Site 1000), Auckland, New Zealand
  • Akershus Universitetssykehus ( Site 3701), Lørenskog, Akershus, Norway
  • Drammen Sykehus, Vestre Viken HF ( Site 3700), Drammen, Buskerud, Norway
  • Nordlandssykehuset ( Site 3704), Bodø, Nordland, Norway
  • Stavanger Universitetssjukehus ( Site 3702), Stavanger, Rogaland, Norway
  • Instituto Regional de Enfermedades Neoplasicas del Centro (IREN CENTRO) ( Site 6605), Concepción, Departamento de Junín, Peru
  • Instituto Regional de Enfermedades Neoplásicas Del Norte ( Site 6606), Trujillo, La Libertad, Peru
  • INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 6604), Surquillo, Muni Metro de Lima, Peru
  • Hospital Guillermo Almenara Irigoyen ( Site 6601), Lima, Peru
  • IPOR Instituto Peruano de Oncología & Radioterapia ( Site 6600), Lima, Peru
  • Oncosalud ( Site 6603), Lima, Peru
  • Hospital Nacional Edgardo Rebagliati Martins ( Site 6602), Lima, Peru
  • Makati Medical Center ( Site 1609), Makati City, National Capital Region, Philippines
  • THE MEDICAL CITY ( Site 1602), Pasig, National Capital Region, Philippines
  • Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 4616), Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Oddzial w Krakowie ( Site 4612), Krakow, Lesser Poland Voivodeship, Poland
  • Specjalistyczny Szpital im. dra A. Sokolowskiego w Walbrzychu ( Site 4604), Wałbrzych, Lower Silesian Voivodeship, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 4609), Warsaw, Masovian Voivodeship, Poland
  • Bialostockie Centrum Onkologii im.M.Sklodowskiej-Curie ( Site 4608), Bialystok, Podlaskie Voivodeship, Poland
  • Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 4600), Słupsk, Pomeranian Voivodeship, Poland
  • Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onko ( Site 4614), Olsztyn, Warmian-Masurian Voivodeship, Poland
  • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie ( Site 4611), Koszalin, West Pomeranian Voivodeship, Poland
  • Salve Medica sp. z o.o. sp. k. ( Site 4618), Lodz, Łódź Voivodeship, Poland
  • Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 4619), Kielce, Świętokrzyskie Voivodeship, Poland
  • Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 4702), Lisbon, Lisbon District, Portugal
  • Hospital de Cascais Doutor José de Almeida ( Site 4700), Lisbon, Portugal
  • Instituto Portugues de Oncologia do Porto ( Site 4705), Porto, Portugal
  • Unidade Local de Saúde de São João ( Site 4703), Porto, Portugal
  • SC Radiotherapy Center Cluj SRL ( Site 4808), Cluj-Napoca, Cluj, Romania
  • Cabinet Medical Oncomed ( Site 4803), Timișoara, Timiș County, Romania
  • Spitalul Clinic Filantropia ( Site 4801), Bucharest, Romania
  • Institutul Oncologic Cluj ( Site 4802), Cluj-Napoca, Romania
  • Institutul Regional de Oncologie ( Site 4805), Iași, Romania
  • King Faisal Specialist Hospital and Research Center ( Site 5400), Riyadh, Riyadh Region, Saudi Arabia
  • National Cancer Centre Singapore ( Site 1700), Singapore, Central Singapore, Singapore
  • CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 4907), Port Elizabeth, Eastern Cape, South Africa
  • Wits Clinical Research ( Site 4903), Johannesburg, Gauteng, South Africa
  • LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 4901), Pretoria, Gauteng, South Africa
  • Sandton Oncology Medical Group (Pty) Ltd ( Site 4900), Sandton, Gauteng, South Africa
  • Cancercare Rondebosch Oncology ( Site 4906), Cape Town, Western Cape, South Africa
  • National Cancer Center ( Site 1800), Goyang-si, Kyonggi-do, South Korea
  • Seoul National University Bundang Hospital ( Site 1801), Kyonggi-do, Kyonggi-do, South Korea
  • Kyungpook National University Chilgok Hospital ( Site 1805), Taegu, Taegu-Kwangyokshi, South Korea
  • Seoul National University Hospital ( Site 1806), Seoul, South Korea
  • Severance Hospital Yonsei University Health System ( Site 1804), Seoul, South Korea
  • Asan Medical Center ( Site 1803), Seoul, South Korea
  • Samsung Medical Center ( Site 1807), Seoul, South Korea
  • The Catholic University of Korea. Seoul St. Mary s Hospital ( Site 1802), Seoul, South Korea
  • Institut Català d'Oncologia - L'Hospitalet ( Site 5001), L'Hospitalet de Llobregat, Barcelona, Spain
  • Hospital de Basurto ( Site 5007), Bilbao, Bizkaia, Spain
  • Complejo asistencial universitario de Salamanca ( Site 5000), Salamanca, Castille and León, Spain
  • HOSPITAL UNIVERSITARIO DE JAEN ( Site 5003), Jaén, Jaen, Spain
  • CHUS - Hospital Clinico Universitario ( Site 5006), Santiago de Compostela, La Coruna, Spain
  • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 5004), Pozuelo de Alarcón, Madrid, Spain
  • Hospital General de Valencia ( Site 5008), Valencia, Valenciana, Comunitat, Spain
  • Parc de Salut Mar - Hospital del Mar ( Site 5005), Barcelona, Spain
  • Hospital Beata María Ana ( Site 5010), Madrid, Spain
  • Hospital Universitario Virgen Macarena ( Site 5002), Seville, Spain
  • Skånes Universitetssjukhus Malmö ( Site 3802), Malmö, Skåne County, Sweden
  • Karolinska Universitetssjukhuset Solna ( Site 3800), Stockholm, Stockholm County, Sweden
  • Akademiska sjukhuset ( Site 3801), Uppsala, Uppsala County, Sweden
  • Södra Älvsborgs Sjukhus Borås ( Site 3804), Borås, Västra Götaland County, Sweden
  • Taichung Veterans General Hospital ( Site 1904), Taichung, Taiwan
  • National Taiwan University Hospital ( Site 1900), Taipei, Taiwan
  • MacKay Memorial Hospital ( Site 1903), Taipei, Taiwan
  • National Taiwan University Cancer Center (NTUCC) ( Site 1901), Taipei, Taiwan
  • Chang Gung Medical Foundation-Linkou Branch ( Site 1906), Taoyuan, Taiwan
  • Faculty of Medicine Siriraj Hospital ( Site 2000), Bangkok, Bangkok, Thailand
  • Chulalongkorn University ( Site 2001), Pathumwan, Bangkok, Thailand
  • Songklanagarind Hospital ( Site 2002), Hat Yai, Changwat Songkhla, Thailand
  • Maharaj Nakorn Chiang Mai Hospital ( Site 2003), Muang, Chiang Mai, Thailand
  • Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 5110), Sıhhiye, Ankara, Turkey (Türkiye)
  • Basken Adana Dr.Turgut Noyan Uygulama ve Arastirma Merkezi. ( Site 5112), Adana, Turkey (Türkiye)
  • Memorial Ankara Hastanesi ( Site 5116), Ankara, Turkey (Türkiye)
  • Ankara Bilkent Şehir Hastanesi. ( Site 5114), Ankara, Turkey (Türkiye)
  • I.U. Cerrahpasa Medical Faculty ( Site 5111), Istanbul, Turkey (Türkiye)
  • Bakirkoy Dr. Sadi Konuk Training and Research Hospital ( Site 5117), Istanbul, Turkey (Türkiye)
  • Erciyes University ( Site 5119), Kayseri, Turkey (Türkiye)
  • Mersin Sehir Eğitim ve Araştırma Hastanesi ( Site 5123), Mersin, Turkey (Türkiye)
  • Samsun Medical Park Hastanesi ( Site 5121), Samsun, Turkey (Türkiye)
  • COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 5207), Cherkasy, Cherkasy Oblast, Ukraine
  • Municipal Enterprise "Bukovinian сlinical oncology сenter" ( Site 5208), Chernivtsi, Chernivetska Oblast, Ukraine
  • CNCE Precarpathian Clinical Oncologic Center ( Site 5201), Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine
  • CNE Regional clinical oncology center of Kirovograd regional Council ( Site 5203), Kropyvnytsky, Kirovohrad Oblast, Ukraine
  • Shalimov Institute of Surgery and Transplantation ( Site 5210), Kyiv, Ukraine
  • University College London Hospital ( Site 5301), London, Camden, United Kingdom
  • Ninewells Hospital and Medical School ( Site 5300), Dundee, Dundee City, United Kingdom
  • Huddersfield Royal Infirmary ( Site 5313), Huddersfield, England, United Kingdom
  • Colchester General Hospital ( Site 5307), Colchester, Essex, United Kingdom
  • Princess Royal University Hospital ( Site 5316), Orpington, Kent, United Kingdom
  • St Bartholomew s Hospital ( Site 5302), London, London, City of, United Kingdom
  • Nottingham University Hospitals NHS Trust ( Site 5314), Nottingham, Nottinghamshire, United Kingdom
  • Belfast City Hospital ( Site 5311), Belfast, United Kingdom
  • Blackpool Victoria Hospital ( Site 5310), Blackpool, United Kingdom
  • Leicester Royal Infirmary ( Site 5309), Leicester, United Kingdom
  • Hanoi Oncology Hospital ( Site 2101), Hanoi, Hanoi, Vietnam
  • K Hospital - National Cancer Hospital ( Site 2100), Hanoi, Hanoi, Vietnam
  • Oncology Hospital ( Site 2102), Ho Chi Minh City, Ho Chi Minh, Vietnam
  • Cho Ray Hospital ( Site 2103), Ho Chi Minh City, Vietnam
Key criteria · Original registry text

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has previously untreated high-risk, early-stage, non-metastatic (M0) breast cancer (BC), defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per AJCC 8th edition criteria as assessed by the physician investigator based on radiological and/or clinical assessment: * cT1c, N1-N2 * cT2, N0-N2 * cT3, N0-N2 * cT4a-d, N0-N2 * The participant must have a centrally confirmed diagnosis of BC that is triple-negative or HR-low+/HER2- (defined as estrogen receptor (ER)-low+ expression in 1% to 10% cells and HER2- as by the most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. * Provides a core needle biopsy from the primary breast tumor at screening to the central laboratory. * Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 28 days before Cycle1 Day 1 (C1D1). * Demonstrates adequate organ function. Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Metastatic (Stage IV) breast cancer or clinical node stage 3 (cN3) nodal involvement * Has received any prior treatment, including radiation, systemic therapy,and/or definitive surgery for currently diagnosed breast cancer * Has undergone excisional biopsy of the primary tumor, axillary lymph node dissection, and/or axillary sentinel lymph node biopsy prior to study treatment. * Received prior systemic anticancer therapy including investigational agents within 4 weeks before C1D1. * Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX- 40, CD137). * Received prior treatment with a TROP2-targeted antibody-drug conjugate (ADC). * Received prior treatment with a topoisomerase I inhibitor-containing ADC. * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. * Known additional malignancy that is progressing or has required active treatment within the past 5 years. * Uncontrolled systemic disease. * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids, has current pneumonitis/interstitial lung disease or has suspected interstitial lung disease (ILD) or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening..

NCT07740707Recruiting

Short-term SCS for Refractory Diabetic Foot Neuropathic Pain

Refractory Diabetic Foot Neuropathic Pain

Why this research matters

Original registry summary

This single-center, assessor-blinded randomized controlled trial enrolls 88 patients with drug-refractory diabetic foot neuropathic pain unsuitable for revascularization surgery. Participants are randomized 1:1 to receive standard diabetic foot care alone (control) or standard care plus 14-day short-term spinal cord stimulation (intervention). The primary outcome is pain remission rate at 6 months, with repeated assessments of microcirculation, nerve function, quality of life and adverse events over 6 months. This study evaluates the efficacy and safety of short-term spinal cord stimulation and develops standardized clinical protocols for this minimally invasive therapy.

Who may participate

Age
18 Years – Not specified
Sex
All
Healthy volunteers
No
Study type
Interventional

Location

  • Nanchong Central Hospital, Nanchong, Sichuan, China
Key criteria · Original registry text

Inclusion Criteria: 1. Age ≥18 years; 2. Confirmed type 2 diabetes mellitus, Wagner grade 1-3 diabetic foot; 3. Persistent moderate-to-severe neuropathic pain (Numeric Rating Scale, NRS ≥4) after ≥3 months of standardized conservative treatment including glycemic control, neurotrophic drugs, multi-modal analgesia and wound care; 4. Contraindications to lower extremity revascularization surgery, persistent pain after revascularization, or voluntary refusal of vascular surgery; 5. Clear consciousness, capable of completing scale assessments and multi-timepoint follow-up; 6. Voluntary participation with signed written informed consent. Exclusion Criteria: 1. Spinal deformity, spinal infection, intraspinal tumor or history of spinal surgery, precluding epidural electrode implantation; 2. Severe coagulation disorders, systemic infection or uncontrolled severe active foot infection; 3. Severe dysfunction of heart, liver, kidney or respiratory system, unable to tolerate minimally invasive operation; 4. Previous spinal cord stimulation or peripheral nerve destructive surgery; 5. Psychiatric disorders interfering with assessment and follow-up cooperation; 6. Pregnant or lactating women; 7. Concurrent enrollment in other clinical trials targeting diabetic foot or chronic pain interventions.

NCT04263285Recruiting

Treatment of Depression Post-SCI

Depression · Spinal Cord Injuries

Why this research matters

Original registry summary

Depression is more common after a spinal cord injury (SCI) than in the general population. Unfortunately, it is unknown how depression is typically treated in individuals with SCI or if commonly used treatment methods are effective. This study will investigate the safety and impact of a novel method for treating depression called repetitive transcranial magnetic stimulation (rTMS). rTMS is a type of non-invasive brain stimulation. Fourteen individuals with a cervical or thoracic level SCI and depression will complete an approved treatment plan using rTMS. Participants will be treated using rTMS five days a week for four weeks. After four weeks of treatment, the study team will review the safety of rTMS and assess changes in depressive symptoms. If the results are positive, larger studies can be designed to develop better treatment options for individuals with SCI and depression.

Who may participate

Age
18 Years – 70 Years
Sex
All
Healthy volunteers
No
Study type
Interventional

Location

  • Medical University of South Carolina, Charleston, South Carolina, United States
Key criteria · Original registry text

Inclusion criteria: 1. Age 18 - 70; 2. At least 6 months post incomplete cervical or incomplete or complete thoracic level SCI; 3. Have at least partial active movement of the right thumb (abductor pollicis brevis) to allow for FDA approved rTMS dosing; 4. Major depressive disorder, as identified through screening tools; 5. No antidepressant medications or no change in doses of psychotropic medication(s) for at least 4 weeks prior to the study (6 weeks if newly initiated medication). Exclusion criteria: 1. Concomitant neurologic diseases/disorders or dementia; 2. Cognitive impairment, as identified through a screening tool (Montreal Cognitive Assessment); 3. History of major head trauma as identified through a screening tool (Ohio State University Traumatic Brain Injury Identification Method); 4. History of psychosis or other Axis I disorder that is primary; 5. Positive screen for bipolar disorder, as identified through a screening tool (The Mood Disorder Questionnaire); 6. Life expectancy \<1 year; 7. Attempt of suicide in the last 2 years; 8. Electronic or metallic implants (i.e. metal in the head, cochlear implant, or pacemaker); 9. History of seizures or currently prescribed anti-seizure medications; 10. Taking medication that increases the risk of seizures; 11. Pregnancy as identified through a positive pregnancy test; 12. Inability or unwillingness of subject or legal guardian/representative to give informed consent.

NCT07553650Recruiting

Master Study Protocol for the Cohort of the Specialty Network Stroke (SN Stroke)(Stroke-CORE)

Intracerebral Haemorrhage · Paediatric Stroke · Stroke Acute · Stroke · Ischemic Stroke

Why this research matters

Original registry summary

The Stroke-CORE cohort aims to provide a comprehensive and up-to-date understanding of stroke care in Germany. To achieve this, patients are followed along the entire continuum of care-from initial management before hospital admission, through acute treatment, rehabilitation, and follow-up care, to the prevention of recurrent strokes. Strokes occurring in childhood are also included in this cohort study. In addition, the study seeks to establish effective structures for the early identification and inclusion of patients in clinical research (screening). In this context, structured screening processes are being implemented across all levels of care at participating sites within the Network University Medicine (NUM), a collaboration of German university hospitals. At the same time, the cohort serves as a platform within this network to systematically address open research questions in various areas of stroke care and to support the targeted planning and conduct of future clinical studies. The study includes patients with ischemic stroke (caused by a blocked blood vessel) or intracerebral hemorrhage (bleeding within the brain). Participation takes place in different thematic modules, each focusing on specific aspects of the disease course and its management. These modules address, among other topics, acute hospital treatment, measures to prevent recurrent strokes (secondary prevention), possible complications, pre-hospital care, rehabilitation, follow-up care, and long-term outcomes such as physical recovery, independence in daily life, and cognitive functions including memory and concentration. As part of the study, a range of data is collected. This includes sociodemographic information (such as age and living situation) as well as medical data, for example on prior conditions, diagnoses, treatments, and comorbidities. In addition, patients' health status is assessed at multiple time points in order to better understand the course of the disease. Depending on the level of participation, data collection may be complemented by the collection of biological samples, such as blood. These are obtained either during routine clinical procedures or through simple, minimally burdensome (non-invasive) methods. The study is structured into several levels that differ in the scope and depth of data collection. The basic level includes essential information, while higher levels involve more detailed assessments. In addition, some levels include the collection of biological samples, and there are optional supplementary modules in which patients may participate voluntarily. This tiered approach allows participation to be flexibly adapted to the individual situation while contributing to a nuanced and comprehensive understanding of stroke care.

Who may participate

Age
Not specified – Not specified
Sex
All
Healthy volunteers
No
Study type
Observational

Location

  • Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg, Free and Hanseatic City of Hamburg, Germany
  • Charité University, Berlin, Germany, Berlin, State of Berlin, Germany
  • Universität Bielefeld, Universitätsklinikum OWL, Evangelisches Klinikum Bethel gGmbH,, Bielefeld, Germany
All listed locations
  • Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany
  • Universitätsklinikum Erlangen, Erlangen, Germany
  • Universitätsklinikum Essen, Essen, Germany
  • Universitätsklinikum Heidelberg, Heidelberg, Germany
  • Universitätsklinikum Leipzig, Leipzig, Germany
  • Universitätsklinikum Schleswig-Holstein (UKSH), Campus Lübeck, Lübeck, Germany
  • Ludwig Maximilians Universität Klinikum, München, Germany
  • Universitätsklinikum Tübingen, Tübingen, Germany
  • Universitätsklinikum Würzburg, Würzburg, Germany
Key criteria · Original registry text

Inclusion Criteria: * Diagnosis of AIS or ICH; the AIS diagnosis may be diagnosed clinically or radiologically (i.e., focal neurological impairment of sudden onset, lasting more than 24 hours and of presumed vascular origin, or with proof of cerebral ischaemia corresponding to the clinical symptoms in neuroimaging); for ICH diagnosis requires clinical symptoms and radiological diagnosis of ICH * Hospital admission \<24h after symptom onset * Age 18+ years for the basic Modules AIS and ICH; age \<18 years for the basic Module paediatric stroke patients * Informed consent: Signed IC from patients capable of giving consent and understanding all content of the IC or IC of an appropriate patient representative or deferred consent, if patients are unable to consent themselves * Additional inclusion criteria are defined by the individual Modules Exclusion Criteria: * In-hospital stroke * TIA * SAH * Stroke as a complication of a medical procedure * Enrolment in a randomised placebo-controlled interventional trial * Already enrolled in the SN STROKE base cohort

NCT06553625Recruiting

Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS

Parkinson Disease · Dystonia · Essential Tremor · Movement Disorders

Why this research matters

Original registry summary

The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.

Who may participate

Age
Not specified – Not specified
Sex
All
Healthy volunteers
No
Study type
Observational

Location

  • Uniklinik Köln, Cologne, Germany
  • Universitaetsklinikum Dusseldorf, Düsseldorf, Germany
  • Universitaetsklinikum Wuerzburg, Würzburg, Germany
All listed locations
  • St. Georges Hospital, London, United Kingdom
Key criteria · Original registry text

Inclusion Criteria: * Study candidate is scheduled to be treated with a commercially approved Boston Scientific RF system for pain or for CNS applications per local Directions for Use (DFU) * Signed a valid, IRB/EC/REB-approved informed consent form Exclusion Criteria: * Meets any contraindications per locally applicable Directions for Use (DFU) * Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments

NCT07943065Recruiting

A Feasibility Study of a Wearable Arrhythmia Monitoring System (PulseON) in Stroke Patients

Cryptogenic Stroke · Atrial Fibrillation (Prevention of Stroke)

Why this research matters

Original registry summary

To evaluate the usability of the Pulse ON wearable device in patients with cryptogenic stroke/TIA

Who may participate

Age
18 Years – Not specified
Sex
All
Healthy volunteers
No
Study type
Observational

Location

  • University Hospital Coventry & Warwickshire NHS Trust, Coventry, United Kingdom
Key criteria · Original registry text

Inclusion Criteria: * Adult patients (\>18yrs old) diagnosed with cryptogenic stroke / TIA * Baseline electrocardiogram (ECG), Holter monitor and echocardiogram as part of the standard of care cardiac work-up in the diagnosis of cryptogenic stroke Exclusion Criteria: * Patients unwilling or unable to wear the PulseON arrhythmia detection device. * Known pre-existing AF or atrial arrhythmia diagnosis. * Participants without capacity will be excluded from this study. * Participants who are pregnant will be excluded from this study.

NCT07778836Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia

Friedreich Ataxia · Friedreich's Ataxia

Why this research matters

Original registry summary

To evaluate the efficacy and safety of subcutaneous nomlabofusp in adult and pediatric subjects with Friedreich's ataxia

Who may participate

Age
12 Years – 40 Years
Sex
All
Healthy volunteers
No
Study type
Interventional

Location

  • Morsani Center for Advanced Health Care, University of South Florida Health, Tampa, Florida, United States
  • Northwestern Medical Group, Department of Neurology, Chicago, Illinois, United States
  • Clinilabs, Eatontown, New Jersey, United States
All listed locations
  • University of Texas Southwestern Medical Center, Dallas, Texas, United States
Key criteria · Original registry text

Key Inclusion Criteria: Subjects who meet all of the following criteria are potentially eligible for study participation: 1. Subject must provide genetically confirmed FRDA diagnosis report and is homozygous for GAA repeat expansions documented on the genetic diagnostic report, with repeat sizing (if available). 2. Subject must complete 1 trial at Screening and 1 trial at Day -1 of the T25-FW test, using their customary assistive device (e.g., cane, 2 canes/crutches \[Canadian crutches\], wheeled walker/rollator or canine assistance) if needed. Each trial must be completed within 3 minutes. 3. Subject must have the following at Screening and Day -1 per the following upright stability items from Module E of the mFARS: 1. Item #E1, Sitting Posture - no more than a maximum score of 2 2. Item #E2A, Stance Feet Apart - no more than a maximum score of 2 (average of 3 attempts) 4. Subject must have an mFARS score ≥ 20 and \< 60 at Screening and Day -1. 5. Subject must have a Functional Staging for Ataxia score of 4 or less at Screening. 6. Subject demonstrates sufficient dexterity and visual acuity to prepare and self-administer SC injections of study drug daily (QD) or has an identified caregiver who will be trained and committed to prepare and administer the injections. 7. Subject has a Screening HbA1c ≤ 7.0%. 8. If the subject is taking permitted concomitant medication(s), subject must have been on a stable dose and frequency of medication(s) over the past 28 days prior to initiation of Screening. Subjects taking niacin and resveratrol must have been on a stable dose and frequency for 90 days prior to initiation of Screening and subjects taking omaveloxolone must have been on a stable dose and frequency for 1 years prior to initiation of Screening. Key Exclusion Criteria Subjects are excluded from the study if any of the following exclusion criteria are met: 1. Subject who is confirmed as compound heterozygous (GAA repeat expansion on only 1 allele) for FRDA. 2. Subject previously participated in a clinical trial involving nomlabofusp. Participation is defined as the subject having signed the informed consent for the study and received at least 1 dose of study drug (nomlabofusp or placebo). 3. The subject has any condition, disease, or situation that could confound the results of the study or put the subject at undue risk, making participation inadvisable in the opinion of the PI. 4. Women of childbearing potential who are pregnant (have a positive pregnancy test at Screening or Day -1), lactating, or planning to attempt to become pregnant during this study or within 90 days after the last dose of study drug (this includes male subjects with partners of childbearing potential who are attempting to become pregnant). 5. Subject used any investigational drug or device within 90 days prior to the initiation of Screening. 6. Subject previously received a gene therapy (investigational or approved) at any time in the past. 7. Subject requires use of amiodarone. 8. Subject used erythropoietin, etravirine, or gamma interferon within 90 days prior to the initiation of Screening. 9. Subject's use of biotin supplementation exceeds 30 μg/day, either as part of a multivitamin or as a standalone supplement, within 7 days prior to the first dose of study drug. Biotin supplementation ≤ 30 μg/day is permitted if taken at a stable dose and frequency for at least 28 days prior to the initiation of Screening and there is a commitment from the subject to maintain the biotin dose throughout the study (due to interference with assays). 10. Subject receives medication that requires SC injection in the abdomen or thigh. 11. Subject has a Screening ECHO left ventricular ejection fraction \< 45%. 12. Subject has a QTcF on an ECG as specified below: 1. For subjects ≥ 12 and \< 18 years of age, a male or female subject with a QTcF \> 460 ms. 2. For subjects ≥ 18 years of age, a male subject with a QTcF \> 450 ms or a female subject has a QTcF \> 470 ms. 13. Subject has suicidal ideation as determined by a "yes" to item #2 on the C-SSRS at Screening (within the last 28 days) or at Day -1.